FDA approved drugs:
(show all 12)
| # |
|
Drug Name |
Active Ingredient(s) 18
|
Company |
Approval Date |
| 1 |
|
Arzerra
18
49
|
OFATUMUMAB |
GlaxoSmithKline |
October 2009 |
Disease/s that Drug Treats:chronic lymphocytic leukemia
Indications and Usage:
18
ARZERRA (ofatumumab) is a CD20-directed cytolytic monoclonal antibodyindicated: in combination with chlorambucil, for the treatment of previouslyuntreated patients with chronic lymphocytic leukemia (CLL) for whomfludarabine-based therapy is considered inappropriate. (1.1) for the treatment of patients with CLL refractory to fludarabine andalemtuzumab. (1.2)
DrugBank Targets:
16
no entry
Mechanism of Action:
18
Target: B-cell
Action: promotes lysis
FDA: Ofatumumab binds specifically to both the small and large extracellular loops of the CD20402 molecule. The CD20 molecule is expressed on normal B lymphocytes (pre-B- to mature403 B-lymphocyte) and on B-cell CLL. The CD20 molecule is not shed from the cell surface and is404 not internalized following antibody binding.405406 The Fab domain of ofatumumab binds to the CD20 molecule and the Fc domain mediates407 immune effector functions to result in B-cell lysis in vitro. Data suggest that possible408 mechanisms of cell lysis include complement-dependent cytotoxicity and antibody-dependent,409 cell-mediated cytotoxicity.
|
| 2 |
|
Bromfenac
18
|
BROMFENAC SODIUM |
Duract, Wyeth-Ayerst Laboratories |
July 1997 |
Disease/s that Drug Treats:acute pain
Indications and Usage:
18
Bromfenac Ophthalmic Solutionis a nonsteroidal anti-inflamatory drug (NSAID) indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract extraction (1).
DrugBank Targets:
16
1. Prostaglandin G/H synthase 2;2. Prostaglandin G/H synthase 1
Mechanism of Action:
18
Target: cyclooxygenas 1 and 2
Action: inhibitor
FDA: Bromfenac is a non-steroidal anti-inflamatory drug (NSAID) that has anti-inflammatory activity. The mechanism of its action is thought to be due to its ability to block prostaglandin synthesis bby inhibiting cyclooxygenase 1 and 2. Prostaglandins have been shown in many animal models to be mediators of certain kinds of intraocular inflammation. In studies performed in animal eyes, prostaglandins have been shown to produces disruption of the blood aqueous humor barrier, vasodilation, increased vascular permeability, leukocytosis, and increased intraocular pressure.
|
| 3 |
|
Lynparza
18
49
|
OLAPARIB |
AstraZeneca |
December 2014 |
Disease/s that Drug Treats:previously treated BRCA mutated advanced ovarian cancer
Indications and Usage:
18
Lynparza is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated asmonotherapy in patients with deleterious or suspected deleterious germlineBRCA mutated (as detected by an FDA-approved test) advanced ovariancancer who have been treated with three or more prior lines of chemotherapy.(1.1)The indication is approved under accelerated approval based on objectiveresponse rate and duration of response. Continued approval for this indicationmay be contingent upon verification and description of clinical benefit inconfirmatory trials. (1 1, 14)
DrugBank Targets:
16
1. Poly [ADP-ribose] polymerase 1;2. Poly [ADP-ribose] polymerase 2;3. Poly [ADP-ribose] polymerase 3
Mechanism of Action:
18
Target: poly (ADP-ribose) polymerase (PARP)
Action: inhibitor
FDA: Lynparza is an inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, including PARP1, PARP2, and PARP3.PARP enzymes are involved in normal cellular homeostasis, such as DNA transcription, cell cycle regulation, and DNArepair. Olaparib has been shown to inhibit growth of select tumor cell lines in vitro and decrease tumor growth in mousexenograft models of human cancer both as monotherapy or following platinum-based chemotherapy. Increasedcytotoxicity and anti-tumor activity following treatment with olaparib were noted in cell lines and mouse tumor modelswith deficiencies in BRCA. In vitro studies have shown that olaparib-induced cytotoxicity may involve inhibition ofPARP enzymatic activity and increased formation of PARP-DNA complex, resulting in disruption of cellular homeostasisand cell death.
|
| 4 |
|
Nexavar
18
49
|
SORAFENIB TOSYLATE |
Bayer/Onyx |
December 2005 |
Disease/s that Drug Treats:Renal Cell Carcinoma
Indications and Usage:
18
NEXAVAR is a kinase inhibitor indicated for the treatment of Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12) Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:
16
1. Serine/threonine-protein kinase B-raf;2. RAF proto-oncogene serine/threonine-protein kinase;3. Vascular endothelial growth factor receptor 3;4. Vascular endothelial growth factor receptor 2;5. Receptor-type tyrosine-protein kinase FLT3;6. Platelet-derived growth factor receptor beta;7. Mast/stem cell growth factor receptor Kit;8. Fibroblast growth factor receptor 1;9. Proto-oncogene tyrosine-protein kinase receptor Ret;10. Vascular endothelial growth factor receptor 1
Mechanism of Action:
18
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-Ã
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surfacekinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-Ã). Several of thesekinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumorgrowth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumorangiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosiswer e obser ved in models of HCC, RCC, and DTC.
|
| 5 |
|
SecreFlo
18
|
SECRETIN SECRETIN SYNTHETIC PORCINE |
Repligen |
April 2002 |
Disease/s that Drug Treats:Pancreatic dysfunction and gastrinoma
Indications and Usage:
18
SecreFlo is indicated for use in secretin stimulation testing for: (1) Stimulation of pancreatic secretions, including bicarbonate, to aid in the diagnosis of pancreatic exocrine dysfunction, (2) Stimulation of gastrin secretion to aid in the diagnosis of gastrinoma.
DrugBank Targets:
16
1. Secretin receptor
Mechanism of Action:
18
Target: secreted pancreatic juices
Action: increase volume and bicarbonate content
FDA: The primary action of SecreFlo is to increase the volume and bicarbonate content ofsecreted pancreatic juices. The standard unit of activity used for SecreFlo is the clinicalunit defined by Jorpes & Mutt in 1966. (1) In the validated cat bioassay, which was usedto define and quantitate the biological activity of secretin and as the release test for thebiologically derived porcine secretin product, SecreFlo demonstrates a potency ofapproximately 5000 clinical units (CU) per milligram of peptide as opposed to 3000 CUper mg for biologically derived porcine secretin. As a pure peptide drug product,SecreFlo⢠dosing is expressed by weight in micrograms. The relationship ofmicrograms of secretin to biological activity is 0.2 mcg = 1 CU.
|
| 6 |
|
Valchlor
18
|
MECHLORETHAMINE HYDROCHLORIDE |
Ceptaris Therapeutics |
August 2013 |
Disease/s that Drug Treats:Stage IA/IB mycosisfungoides-type cutaneous T-cell lymphoma
Indications and Usage:
18
VALCHLOR is an alkylating drug indicated for the topical treatmentof Stage IA and IB mycosis fungoidesâtype cutaneous Tâcelllymphoma in patients who have received prior skinâdirected therapy(1). Â
DrugBank Targets:
16
1. DNA
Mechanism of Action:
18
Target: rapidly-proliferating cells
Action: inhibitor
FDA: Mechlorethamine, also known as nitrogen mustard, is an alkylating agent which inhibits rapidly proliferating cells.
|
| 7 |
|
Zuplenz
18
|
ONDANSETRON |
Strativa Pharmaceuticals |
July 2010 |
Disease/s that Drug Treats:post-operative, chemotherapy and radiotherapy induced nausea and vomiting
Indications and Usage:
18
ZUPLENZ is a 5-HT3 receptor antagonist indicated for: Prevention of nausea and vomiting associated with highly emetogenic cancerchemotherapy. (1.1) Prevention of nausea and vomiting associated with initial and repeat coursesof moderately emetogenic cancer chemotherapy. (1.2) Prevention of nausea and vomiting associated with radiotherapy in patientsreceiving total body irradiation, single high-dose fraction to abdomen, ordaily fractions to the abdomen. (1.3) Prevention of postoperative nausea and/or vomiting. (1.4)
DrugBank Targets:
16
1. 5-hydroxytryptamine receptor 3A;2. 5-hydroxytryptamine receptor 4;3. Mu-type opioid receptor;4. 5-hydroxytryptamine receptor 1A;5. 5-hydroxytryptamine receptor 1B
Mechanism of Action:
18
Target: 5-HT3 receptor
Action: selective antagonist
FDA: Ondansetron is a selective 5-HT3 receptor antagonist. While its mechanism of action has not been fully characterized, ondansetron isnot a dopamine-receptor antagonist. Serotonin receptors of the 5-HT3 type are present both peripherally on vagal nerve terminals andcentrally in the chemoreceptor trigger zone of the area postrema. It is not certain whether ondansetronâ s antiemetic action is mediatedcentrally, peripherally, or in both sites. However, cytotoxic chemotherapy appears to be associated with release of serotonin from theenterochromaffin cells of the small intestine. In humans, urinary 5-HIAA (5-hydroxyindoleacetic acid) excretion increases aftercisplatin administration in parallel with the onset of emesis. The released serotonin may stimulate the vagal afferents through the 5-HT3 receptors and initiate the vomiting reflex. In animals, the emetic response to cisplatin can be prevented by pretreatment with aninhibitor of serotonin synthesis, bilateral abdominal vagotomy and greater splanchnic nerve section, or pretreatment with a serotonin5-HT3 receptor antagonist.
|
| 8 |
|
Zytiga
18
49
|
ABIRATERONE ACETATE |
Centocor Ortho Biotech |
May 2011 |
Disease/s that Drug Treats:prostate cancer
Indications and Usage:
18
ZYTIGA is a CYP17 inhibitor indicated in combination with prednisone forthe treatment of patients with metastatic castration-resistant prostate cancer.(1)
DrugBank Targets:
16
1. Steroid 17-alpha-hydroxylase/17,20 lyase
Mechanism of Action:
18
Target: 17 α-hydroxylase/C17,20-lyase (CYP17)
Action: inhibitor
FDA: Abiraterone acetate (ZYTIGA) is converted in vivo to abiraterone, an androgen biosynthesisinhibitor, that inhibits 17 α-hydroxylase/C17,20-lyase (CYP17). This enzyme is expressed intesticular, adrenal, and prostatic tumor tissues and is required for androgen biosynthesis.CYP17 catalyzes two sequential reactions: 1) the conversion of pregnenolone andprogesterone to their 17α-hydroxy derivatives by 17α-hydroxylase activity and 2) thesubsequent formation of dehydroepiandrosterone (DHEA) and androstenedione,respectively, by C17, 20 lyase activity. DHEA and androstenedione are androgens and areprecursors of testosterone. Inhibition of CYP17 by abiraterone can also result in increasedmineralocorticoid production by the adrenals [see Warnings and Precautions (5.1)].Androgen sensitive prostatic carcinoma responds to treatment that decreases androgenlevels. Androgen deprivation therapies, such as treatment with GnRH agonists ororchiectomy, decrease androgen production in the testes but do not affect androgenproduction by the adrenals or in the tumor. ZYTIGA decreased serum testosterone and other androgens in patients in theplacebo-controlled Phase 3 clinical trial. It is not necessary to monitor the effect of ZYTIGAon serum testosterone levels.Changes in serum prostate specific antigen (PSA) levels may be observed but have not beenshown to correlate with clinical benefit in individual patients.
|
| 9 |
|
Astelin nasal spray
18
|
AZELASTINE HYDROCHLORIDE |
Wallace Laboratories |
November 1996 |
Disease/s that Drug Treats:seasonal allergic rhinitis
Indications and Usage:
18
Astelin Nasal Spray is an H1-receptor antagonist indicated for the treatment of the symptoms of seasonal allergic rhinitis in adults and pediatric patients 5 years and older and for the treatment of the symptoms o
DrugBank Targets:
16
Histamine H1 receptor
Mechanism of Action:
18
Target: -
Action: -
FDA: Azelastine hydrochloride, a phthalazinone derivative, exhibits histamine H1-receptor antagonist activity in isolated tissues, animal models, and humans. Astelin Nasal Spray is administered as a racemic mixture with no difference in pharmacologic activity noted between the enantiomers in in vitro studies. The major metabolite, desmethylazelastine, also possesses H1-receptor antagonist activity.
|
| 10 |
|
Cayston
18
|
AZTREONAM |
Gilead |
February 2010 |
Disease/s that Drug Treats:cystic fibrosis patients with Pseudomonas aeruginosa
Indications and Usage:
18
CAYSTON is a monobactam antibacterial indicated to improve respiratory symptoms in cystic fibrosis (CF) patients with Pseudomonas aeruginosa. Safety and effectiveness have not been established in pediatric patients below the age of 7 years, patients with FEV1 <25% or >75% predicted, or patients colonized with Burkholderia cepacia. (1)
DrugBank Targets:
16
Penicillin-binding protein 3|Beta-lactamase
Mechanism of Action:
18
Target: penicillin binding proteins of susceptible bacteria
Action: inhibition of bacterial cell wall synthesis
FDA: Aztreonam is an antibacterial drug [see Clinical Pharmacology (12.4)]. Aztreonam exhibits activity in vitro against Gram-negative aerobic pathogens including P. aeruginosa. Aztreonam binds to penicillinbinding proteins of susceptible bacteria, which leads to inhibition of bacterial cell wall synthesis and death of the cell. Aztreonam activity is not decreased in the presence of CF lung secretions.
|
| 11 |
|
Cefazolin and Dextrose USP
18
|
CEFAZOLIN SODIUM |
B Braun Medical |
July 2000 |
Disease/s that Drug Treats:Various bacterial infections, septicemia, endocarditis, and perioperative prophylaxis
Indications and Usage:
18
Cefazolin for Injection USP and Dextrose Injection USP is a cephalosporin antibacterial indicated in the treatment of the following infections caused by susceptible isolates of the designated microorganisms: Respiratory tract infections (1.1); urinary tract infections (1.2); skin and skin structure infections (1.3); biliary tract infections (1.4); bone and joint infections (1.5); genital infections (1.6); septicemia (1.7); endocarditis (1.8) and perioperative prophylaxis (1.9).
DrugBank Targets:
16
Penicillin-binding protein 1A|Penicillin-binding protein 1B|Penicillin-binding protein 1C|Penicillin-binding protein 2
Mechanism of Action:
18
Target: -
Action: -
FDA: Cefazolin is an antibacterial drug [see Microbiology (12.4)]. Cefazolin is a bactericidal agent that acts by inhibition of bacterial cell wall synthesis.
|
| 12 |
|
Qnasl
18
|
BECLOMETHASONE DIPROPIONATE |
Teva Pharmaceutical |
March 2012 |
Disease/s that Drug Treats:seasonal and perennial allergic rhinitis
Indications and Usage:
18
QNASL Nasal Aerosol is a corticosteroid indicated for the treatment of nasal symptoms associated with seasonal and perennial allergic rhinitis in patients 4 years of age and older. (1.1)
DrugBank Targets:
16
Glucocorticoid receptor
Mechanism of Action:
18
Target: -
Action: anti-inflammatory
FDA: Beclomethasone dipropionate is a prodrug that is extensively converted to the active metabolite, beclomethasone-17-monopropionate. The precise mechanism through which beclomethasone dipropionate affects rhinitis symptoms is unknown. Corticosteroids have been shown to have multiple anti-inflammatory effects, inhibiting both inflammatory cells (e.g., mast cells, eosinophils, basophils, lymphocytes, macrophages, and neutrophils) and the release of inflammatory mediators (e.g., histamine, eicosanoids, leukotrienes, and cytokines). Beclomethasone-17-monopropionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor which is approximately 13 times that of dexamethasone, 6 times that of triamcinolone acetonide, 1.5 times that of budesonide and 25 times that of beclomethasone dipropionate. The clinical significance of these findings is unknown.
|
Drugs for Mycosis Fungoides (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 370)
| # |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
| 1 |
|
Methoxsalen |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
298-81-7 |
4114
|
|
Synonyms:
12692-94-3
298-81-7
5-19-06-00015 (Beilstein Handbook Reference)
5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, .delta.-lactone
5-Benzofuranacrylic acid, 6-hydroxy-7-methoxy-, delta-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylate delta-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylate δ-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylic acid delta-lactone
6-Hydroxy-7-methoxy-5-benzofuranacrylic acid δ-lactone
7-Furocoumarin
8 Methoxypsoralen
8 MOP
8-Methoxy
8-Methoxy(furano-3'.2':6.7-coumarin)
8-Methoxy-(furano-3'.2':6.7-coumarin)
8-Methoxy-[furano-3'.2':6.7-coumarin]
8-Methoxy-2',3',6,7-furocoumarin
8-Methoxy-4',5',6,7-furocoumarin
8-Methoxy-4',5':6,7-furocoumarin
8-Methoxyfuranocoumarin
8-methoxyfuranocoumarins
8-methoxyfurocoumarins
8-Methoxypsoralen
8-METHOXYPSORALEN + UVA (SEE ALSO C55903)
8-Methoxypsoralen with ultraviolet A therapy
8-Methoxypsoralene
8MO
8MOP
8-MOP
8-MP
9-(methyloxy)-7H-furo[3,2-g]chromen-7-one
9-metho xy-7H-furo(3,2-g)benzopyran-7-one
9-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one
9-Methoxy-7H-furo(3,2-g)benzopyran-7-one
9-Methoxy-7H-furo[3,2-g][1]benzopyran-7-one
9-Methoxy-7H-furo[3,2-g]chromen-7-one
9-Methoxyfuro(3,2-g)chromen-7-one
9-Methoxyfuro[3,2-g][1]benzopyran-7-one
9-methoxyfuro[3,2-g]chromen-7-one
9-Methoxypsoralen
A1783/0075596
AC1L1HFY
AC-4259
ACon1_000174
AKOS000277012
Ammodin
Ammoidin
an 8-methoxyfurocoumarin
Boehringer ingelheim brand OF methoxsalen
Boehringer Ingelheim Brand of Methoxsalen
BPBio1_000680
BRD-K63430059-001-03-2
BRD-K63430059-001-06-5
BRN 0196453
BSPBio_000618
BSPBio_001997
C01864
Canderm brand OF methoxsalen
Canderm Brand of Methoxsalen
CAS-298-81-7
CCRIS 2083
CHEBI:18358
CHEBI:52028
CHEMBL416
Chinoin brand OF methoxsalen
Chinoin Brand of Methoxsalen
CID4114
CPD000071170
CPD-13042
D00139
D008730
DB Brand of Methoxsalen
DB Brand OF methoxsalen
DB00553
Delta Brand of Methoxsalen
Delta Brand OF methoxsalen
Deltasoralen
Dermatech brand OF methoxsalen
Dermatech Brand of Methoxsalen
Dermox
DivK1c_000763
EINECS 206-066-9
FT-0082222
Galderma brand OF methoxsalen
Galderma Brand of Methoxsalen
Geroxalen
HMS1569O20
HMS1920N05
HMS2091D20
HMS502G05
HSDB 2505
I06-0695
ICN brand 1 OF methoxsalen
ICN Brand 1 of Methoxsalen
ICN brand 2 OF methoxsalen
ICN Brand 2 of Methoxsalen
ICN brand 3 OF methoxsalen
ICN Brand 3 of Methoxsalen
IDI1_000763
Jsp005650
KBio1_000763
KBio2_001503
KBio2_004071
KBio2_006639
KBio3_001497
KBioGR_000543
KBioSS_001503
LS-68
M3501_FLUKA
M3501_SIAL
MEGxp0_000095
Meladinin
|
Meladinin (VAN)
Meladinina
Meladinine
Méladinine
Meladoxen
Meloxine
Methoxa dome
Methoxa Dome
Methoxa-dome
Methoxa-Dome
Methoxalen
Methoxaten
methoxsalen
Methoxsalen
Methoxsalen (JP15/USP)
Methoxsalen [BAN:JAN]
Methoxsalen canderm brand
Methoxsalen Canderm Brand
Methoxsalen chinoin brand
Methoxsalen Chinoin Brand
Methoxsalen Delta brand
Methoxsalen Delta Brand
Methoxsalen dermatech brand
Methoxsalen Dermatech Brand
Methoxsalen mex-america brand
Methoxsalen Mex-America Brand
Methoxsalen plus ultraviolet radiation
Methoxsalen sanofi-synthelabo brand
Methoxsalen Sanofi-Synthelabo Brand
Methoxsalen with ultra-violet A theraphy
Méthoxsalène
Methoxy-8-psoralen
Mex america brand OF methoxsalen
Mex America Brand of Methoxsalen
Mex-america brand OF methoxsalen
Mex-America Brand of Methoxsalen
MLS000062633
MLS002303011
MolPort-000-696-480
NCGC00016418-01
NCGC00060938-02
NCGC00060938-03
NCGC00060938-04
NCGC00060938-05
NCGC00060938-06
NCGC00178871-01
NCGC00178871-02
NCGC00178871-03
NCI60_004085
NCI-C55903
New-Meladinin
NINDS_000763
NSC 45923
NSC45923
O-methylxanthotoxol
O-Methylxanthotoxol
Oprea1_166319
Oxoralen
Oxsoralen
OXSORALEN (TN)
Oxsoralen lotion
Oxsoralen Lotion
Oxsoralen Ul tra
Oxsoralen ultra
Oxsoralen Ultra
Oxsoralen-ultra
Oxsoralen-Ultra
Oxypsoralen
Prestwick_661
Prestwick0_000479
Prestwick1_000479
Prestwick2_000479
Prestwick3_000479
Proralone-mop
Proralone-Mop
Psoralen-mop
Psoralen-Mop
Psoralon-MOP
Puvalen
Puvamet
S1952_Selleck
SAM002548974
Sanofi synthelabo brand OF methoxsalen
Sanofi Synthelabo Brand of Methoxsalen
Sanofi-synthelabo brand OF methoxsalen
Sanofi-Synthelabo Brand of Methoxsalen
SDCCGMLS-0042377.P002
SMR000071170
SPBio_001004
SPBio_002557
Spectrum_001023
SPECTRUM1500400
Spectrum2_001052
Spectrum3_000499
Spectrum4_000052
Spectrum5_001891
STK735539
STOCK1N-03091
Ultra mop
Ultra Mop
Ultramop
Ultramop Lotion
UNII-U4VJ29L7BQ
Uvadex
WLN: T C566 DO LVOJ BO1
X0009
Xanthotoxin
XANTHOTOXIN
Xanthotoxine
Xanthoxin
Zanthotoxin
ZINC02548959
|
|
| 2 |
|
Bexarotene |
Approved, Investigational |
Phase 4,Phase 3,Phase 2,Phase 1 |
|
153559-49-0 |
82146
|
|
Synonyms:
153559-49-0
3-methyl-TTNEB
3-Methyl-ttneb
4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(3,5,5,8,8-Pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid
4-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthalenyl)ethenyl)benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydronaphthalen-2-yl)vinyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyl-6,7-dihydronaphthalen-2-yl)ethenyl]benzoic acid
4-[1-(3,5,5,8,8-pentamethyltetralin-2-yl)ethenyl]benzoic acid
4-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphtalenyl)ethenyl]benzoic acid
4-[1-3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthaleneyl)vinyl]benzene carboxylic acid
9RA
AC1L32UG
Bexaroten
Bexarotene
Bexarotène
Bexarotene (USAN/INN)
Bexarotene [USAN]
bexaroteno
Bexaroteno
bexarotenum
Bexarotenum
BIDD:PXR0021
C095105
CHEBI:50859
CHEMBL1023
CID82146
D03106
DB00307
Elan brand of bexarotene
|
Elan brand OF bexarotene
HMS2089L14
HSDB 7453
I14-1941
LG 1069
LG100069
LG-100069
LG1069
LG69 compound
LG69 Compound
LGD 1069
LGD1069
LGD-1069
Ligand brand of bexarotene
Ligand brand OF bexarotene
LS-38306
MolPort-003-845-030
NCGC00181016-01
P-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-Pentamethyl-2-naphthyl)vinyl)benzoate
p-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
P-(1-(5,6,7,8-tetrahydro-3,5,5,8,8-Pentamethyl-2-naphthyl)vinyl)benzoic acid
P-(1-(5,6,7,8-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl)benzoic acid
p-[1-(5,6,7,8,-Tetrahydro-3,5,5,8,8-pentamethyl-2-naphthyl)vinyl]benzoic acid
SBB067189
Targret
Targretin
Targretin (TN)
Targretin-gel
Targretyn
Targrexin
UNII-A61RXM4375
|
|
| 3 |
|
leucovorin |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
58-05-9 |
6006
143
|
|
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R,S)-5-Formyltetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-formyltetrahydrofolic acid
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
Acid, folinic
Acide folinique
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
Citrovorum factor
Factor, citrovorum
folinate
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
|
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monosodium salt
Leucovorinum
Leukovorin
Leukovorum
Levoleucovorin
L-leucovorin
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
Rescuvolin
Welcovorin
Wellcovorin
|
|
| 4 |
|
Methotrexate |
Approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
59-05-2, 1959-05-2 |
126941
|
|
Synonyms:
4-amino-10-Methylfolate
4-amino-10-methylfolic acid
4-amino-10-Methylfolic acid
4-amino-N(10)-Methylpteroylglutamate
4-amino-N(10)-methylpteroylglutamic acid
4-amino-N(10)-Methylpteroylglutamic acid
Abitrexate
Amethopterin
Amethopterine
Antifolan
Arbitrexate
Dicesium salt methotrexate
Emtexate
Emtexic acid
Folex
HDMTX
Hydrate, methotrexate
L-Amethopterin
Ledertrexate
Ledertrexic acid
Metatrexan
Methopterin
Methotextrate
Methotrate
Methotrexat
|
Méthotrexate
Methotrexate hydrate
Methotrexate sodium
Methotrexate Sodium
Methotrexate, (D)-isomer
Methotrexate, (DL)-isomer
Methotrexate, dicesium salt
Methotrexate, disodium salt
Methotrexate, sodium salt
Methotrexatum
Methotrexic acid
Methylaminopterin
Methylaminopterinum
Metotrexato
Mexate
MTX
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamate
N-[4-[[(2,4-diamino-6-pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-[4-[[(2,4-diamino-6-Pteridinyl)methyl]methylamino]benzoyl]-L-glutamic acid
N-Bismethylpteroylglutamic acid
N-Bismethylpteroylglutamic Acid
Rheumatrex
Sodium, methotrexate
Trexall
|
|
| 5 |
|
Denileukin diftitox |
Approved, Investigational |
Phase 4,Phase 2,Not Applicable |
|
173146-27-5 |
|
|
Synonyms:
|
|
Interleukin-2/diptheria toxin fusion protein
|
|
| 6 |
|
Folic Acid |
Approved, Nutraceutical, Vet_approved |
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
59-30-3 |
6037
|
|
Synonyms:
(2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid
01769_FLUKA
2d0k
33609-88-0
36653-55-1 (mono-potassium salt)
59-30-3
6484-89-5 (mono-hydrochloride salt)
AC-11682
AC1L1LNX
Acfol (Spain)
Acide folique
Acide folique [INN-French]
Acido folico
Acido folico [INN-Spanish]
Acidum folicum
Acidum folicum [INN-Latin]
Acifolic
AI3-26387
AKOS000503224
Antianemia factor
Apo-Folic
ARONIS014410
b9, Vitamin
BIDD:ER0563
BIDD:GT0641
BIF0608
bmse000299
BPBio1_000654
BSPBio_000594
BSPBio_002338
C00504
C20H20N6O6
CAS-59-30-3
CCRIS 666
CHEBI:27470
CHEMBL1622
CID6037
CPD000471860
Cytofol
D00070
DB00158
DivK1c_000494
Dosfolat b activ
Dosfolat B activ
EINECS 200-419-0
F0043
F7876_SIAL
F7876_SIGMA
F8758_SIGMA
F8798_SIAL
F8890_SIGMA
Facid
Factor U
FOL
Folacid
Folacin
Folaemin
Folaemin [Netherlands]
Folan
Folasic (Australia)
Folate
Folbal
Folcidin
Folcidin (VAN)
Folcysteine
Foldine
Foldine [France]
Folettes
Foliamin
Folic
folic acid
Folic acid (JP15/USP/INN)
Folic acid (TN)
Folic acid [BAN:INN:JAN]
Folic acid [INN:BAN:JAN]
Folic acid dihydrate
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
Folicet
Folicet (TN)
Folico
Folico (Italy)
Folina
Folina (Italy)
Folipac
|
Folsaeure
Folsan
Folsaure
Folsäure
Folsav
Folvite
Folvron
Glutamic acid, N-(p-(((2-amino-4-hydroxypyrimido(4,5-b)pyrazin-6-yl)methyl)amino)benzoyl)-, L
HMS1921D20
HMS2092N17
HMS501I16
HSDB 2002
IDI1_000494
Incafolic
InChI=1/C19H19N7O6/c20-19-25-15-14(17(30)26-19)23-11(8-22-15)7-21-10-3-1-9(2-4-10)16(29)24-12(18(31)32)5-6-13(27)28/h1-4,8,12,21H,5-7H2,(H,24,29)(H,27,28)(H,31,32)(H3,20,22,25,26,30)/t12-/m0/s
KBio1_000494
KBio2_001861
KBio2_004429
KBio2_006997
KBio3_001558
KBioGR_002222
KBioSS_001861
Kyselina listova
Kyselina listova [Czech]
Liver lactobacillus casei factor
Liver Lactobacillus casei factor
LS-2157
Millafol
Mission prenatal
Mittafol
MLS001304016
MLS001335861
MolPort-004-285-551
N-(4-(((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzo- yl)-L-glutamic acid
N-(4-((2-Amino-1,4-dihydro-4-oxo-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(4-{[(2-amino-4-oxo-3,4-dihydropteridin-6-yl)methyl]amino}benzoyl)-L-glutamic acid
N-(p-(((2-Amino-4-hydroxy-6-pteridinyl)methyl)amino)benzoyl)-L-glutamic acid
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamic acid
N-[4-[[(2-amino-3,4-dihydro-4-oxo-6-Pteridinyl)methyl]amino]benzoyl]-L-glutamic acid
NCGC00016265-01
NCGC00142391-01
nchembio.108-comp10
Nifolin
Nifolin [Denmark]
NINDS_000494
Novofolacid
Novofolacid [Canada]
N-Pteroyl-L-glutamate
N-pteroyl-L-glutamic acid
N-Pteroyl-L-glutamic acid
NSC 3073
PGA
PGA (VAN)
Prestwick_230
Prestwick3_000627
PteGlu
Pteroylglutamate
Pteroylglutamic acid
Pteroyl-L-glutamate
Pteroyl-L-glutamic acid
Pteroyl-L-monoglutamate
Pteroyl-L-monoglutamic acid
Pteroylmonoglutamate
Pteroylmonoglutamic acid
SAM002264616
SDCCGMLS-0066738.P001
Serum Folate Level
SMP2_000137
SMR000471860
SPBio_001357
Spectrum_001381
SPECTRUM1502020
Spectrum2_001459
Spectrum3_000749
Spectrum4_001751
Spectrum5_000602
UNII-935E97BOY8
Usaf cb-13
Vitamin B11
Vitamin b9
Vitamin B9
Vitamin Bc
Vitamin BC
Vitamin be
Vitamin Be
Vitamin m
Vitamin M
|
|
| 7 |
|
Dermatologic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 8 |
|
Photosensitizing Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 9 |
|
Pharmaceutical Solutions |
|
Phase 4,Phase 2,Phase 1,Not Applicable |
|
|
|
| 10 |
|
Protective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 11 |
|
Nucleic Acid Synthesis Inhibitors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 12 |
|
Vitamin B9 |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 13 |
|
Antiviral Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 14 |
|
Immunologic Factors |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
| 15 |
|
Vitamin B Complex |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 16 |
|
Antimetabolites, Antineoplastic |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 17 |
|
Anti-Infective Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 18 |
|
Immunosuppressive Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
| 19 |
|
Antimetabolites |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable |
|
|
|
| 20 |
|
Antirheumatic Agents |
|
Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
| 21 |
|
Folic Acid Antagonists |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 22 |
|
Folate |
|
Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 |
|
|
|
| 23 |
|
interferons |
|
Phase 4,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
|
|
| 24 |
|
Interferon-alpha |
|
Phase 4,Phase 2,Not Applicable |
|
|
|
| 25 |
|
Clorazepate Dipotassium |
|
Phase 4 |
|
|
|
| 26 |
|
Ketamine |
Approved, Vet_approved |
Phase 3 |
|
6740-88-1 |
3821
|
|
Synonyms:
(-)-Ketamine
(+-)-Ketamine
(+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
(+/-)-Ketamine
(±)-ketamine
(S)-(-)-Ketamine
(S)-Ketamine
100477-72-3
2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(2-chloro-Phenyl)-2-methylamino-cyclohexanone
2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone
2-(methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(methylamino)-2-(2-Chlorophenyl)cyclohexanone
2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone
2-(o-chlorophenyl)-2-(methylamino)-cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone
2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone
2-(O-Chlorophenyl)-2-(methylamino)-cyclohexanone
33643-45-7
6740-88-1
79499-51-7
AC1L1GSH
AC1Q40UR
AKOS001053247
BRN 2216965
C07525
C13H16ClNO
Calipsol
Calypsol
Cetamina
Cetamina [INN-Spanish]
CHEBI:138833
CHEBI:6121
CHEMBL742
CI 581 base
CI-581
CID3821
CLSTA 20
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI)
Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI)
Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)
D08098
DB01221
DEA No. 7285
DivK1c_000217
|
dl-Ketamine
DL-ketamine
DL-Ketamine
EINECS 229-804-1
Esketamine
Green
IDI1_000217
Kalipsol
KBio1_000217
Ketaject
Ketalar
Ketalar base
Ketamina
ketamine
Kétamine
Ketamine (INN)
Ketamine [INN:BAN]
Ketamine base
Ketamine Base
Ketamine HCL
KETAMINE HCL
Ketamine hydrochloride
Ketaminum
Ketaminum [INN-Latin]
Ketanest
Ketaset
Ketoject
Ketolar
l-Ketamine
L-Ketamine
LS-57301
MLS001331674
MolPort-001-838-070
NCGC00159480-02
NCGC00159480-03
NINDS_000217
NMDA
NSC 70151
NSC70151
SMR000238141
Special K
Special K [street name]
T385
Tekam
Tekam (TN)
UNII-690G0D6V8H
|
|
| 27 |
|
Orange |
Approved |
Phase 3 |
|
|
|
| 28 |
|
Ciprofloxacin |
Approved, Investigational |
Phase 3,Not Applicable |
|
85721-33-1 |
2764
|
|
Synonyms:
17850_FLUKA
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylate
1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperzinyl)-3-quinolinecarboxylic acid HCl H2O
1-Cyclopropyl-6-fluoro-1,4-dihydro-7-(1-piperazinyl)-4-oxo-3-quinoline carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylate
1-cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydroquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylate
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-quinoline-3-carboxylic acid
1-CYCLOPROPYL-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydroquinoline-3-carboxylIC ACID
1-CYCLOPROPYL-6-FLUORO-4-OXO-7-PIPERAZIN-1-YL-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylate
1-cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-4-oxo-7-piperazin-1-ylquinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylate
1-Cyclopropyl-6-fluoro-7-(4-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylate
1-cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
1-Cyclopropyl-6-fluoro-7-hexahydro-1-pyrazinyl-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid
33434_FLUKA
33434_RIEDEL
3-Quinolinecarboxylic acid,1,4-dihydro-1-cyclopropyl-6-fluoro-4-oxo-7-(1-piperazinyl)
85721-33-1
AC1L1EEW
AC-7613
AKOS000269653
Alcon Cilox
Anhydrous, ciprofloxacin hydrochloride
ARONIS020379
Bacquinor
Baflox
BAS 06989041
Bay o 9867
Bay o 9867 (*Hydrochloride*)
BAY q 3939
Bay-09867
Baycip
BAYQ3939
BAY-Q-3939
Bernoflox
Bi-Cipro
BIDD:GT0205
Bio-0540
BPBio1_000140
BRD-K04804440-311-02-3
BRN 3568352
BSPBio_000126
BSPBio_003344
C05349
C17H18FN3O3
CAS-93107-08-5
CBMicro_048498
CCRIS 5241
CHEBI:100241
CHEMBL8
CID2764
Ciflox
Cifloxin
Cilab
Ciloxan
Ciloxan (*Hydrochloride*)
Ciplus
Ciprecu
Ciprinol
Cipro
Cipro (*Hydrochloride*)
Cipro (TN)
Cipro I.V.
CIPRO IN DEXTROSE 5% IN PLASTIC CONTAINER
CIPRO IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
Cipro IV
Cipro XL
Cipro XR
Ciprobay
Ciprobay Uro
Ciprocinol
Ciprodar
Ciproflox
ciprofloxacin
Ciprofloxacin (JAN/USP/INN)
Ciprofloxacin [USAN:INN:BAN]
Ciprofloxacin dihydrochloride
Ciprofloxacin HCl
Ciprofloxacin Hydrchloride
Ciprofloxacin hydrochloride
Ciprofloxacin hydrochloride anhydrous
Ciprofloxacin monohydrochloride
Ciprofloxacin monohydrochloride monohydrate
Ciprofloxacina
Ciprofloxacine
Ciprofloxacine [INN-French]
Ciprofloxacino
|
Ciprofloxacino [INN-Spanish]
Ciprofloxacinum
Ciprofloxacinum [INN-Latin]
Ciprogis
Ciprolin
Ciprolon
Cipromycin
Ciproquinol
Ciprowin
Ciproxan
Ciproxin
Ciproxina
Ciproxine
Ciriax
Citopcin
Cixan
Corsacin
CPF
CPFX
CRL-1605 & Ciprofloxacin
Cycin
Cyprobay
D00186
DB00537
DivK1c_000095
Eni
Fimoflox
Flociprin
Floxin
HMS1922E18
HMS2090O07
HMS2093I03
HMS500E17
HSDB 6987
Hydrochloride anhydrous, ciprofloxacin
Hydrochloride, ciprofloxacin
IDI1_000095
Ipiflox
Italnik
KBio1_000095
KBio2_000642
KBio2_003210
KBio2_005778
KBio3_002846
KBioGR_001567
KBioSS_000642
Liposomal-ciprofloxacin
Loxan
LS-141563
MLS001336035
MolPort-000-819-654
Monohydrate, ciprofloxacin monohydrochloride
Monohydrochloride monohydrate, ciprofloxacin
NCGC00016959-01
NCGC00095058-01
NCGC00095058-02
NCGC00178128-01
nchembio820-comp1
NINDS_000095
NSC620634
Ocuflox
Oprea1_008239
Oprea1_313572
Prestwick0_000113
Prestwick1_000113
Prestwick2_000113
Prestwick3_000113
Probiox
Proflaxin
Proflox
Proksi 250
Proksi 500
Proquin XR
Quinolid
Quintor
Rancif
Roxytal
Septicide
SMP1_000125
SMR000471901
Sophixin Ofteno
SPBio_001474
SPBio_002065
Spectrum_000162
SPECTRUM1503614
Spectrum2_001567
Spectrum3_001872
Spectrum4_000874
Spectrum5_001089
Spitacin
STK021082
Superocin
Unex
UNII-5E8K9I0O4U
Velomonit
Zumaflox
|
|
| 29 |
|
Amoxicillin |
Approved, Vet_approved |
Phase 3,Not Applicable |
|
26787-78-0 |
33613
|
|
Synonyms:
(-)-6-(2-Amino-2-(P-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo-(3.2.0)heptane-2-carboxylic acid
(2S,5R,6R)-6-[[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
(2S,5R,6R)-6-{[(2R)-2-amino-2-(4-hydroxyphenyl)acetyl]amino}-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
26787-78-0
33911-69-2
34642-77-8 (mono-hydrochloride salt)
4-Thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid, 6-(2-amino-2-(p-hydroxyphenyl)acetamido)-3,3-dimethyl-7-oxo-, D- (8CI)
6-(a-amino-4-hydroxyphenylacetamido)Penicillanic acid
6-(D-(-)-alpha-Amino-p-hydroxyphenylacetamido)penicillanic acid
6-(D-(-)-p-Hydroxy-alpha-aminobenzyl)penicillin
6-(D-(-)-P-Hydroxy-alpha-aminobenzyl)penicillin
6-(P-Hydroxy-a-aminophenylacetamido)penicillanate
6-(P-Hydroxy-a-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanate
6-(p-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-alpha-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanate
6-(p-hydroxy-α-aminophenylacetamido)penicillanic acid
6-(P-Hydroxy-α-aminophenylacetamido)penicillanic acid
6-[[amino(4-Hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 9ci
61336-70-7 (TRIHYDRATE)
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carbonyl
6beta-[(2R)-2-amino-2-(4-hydroxyphenyl)acetamido]-2,2-dimethylpenam-3alpha-carboxylic acid
71447-36-4
81030-75-3
a-amino-P-Hydroxybenzylpenicillin
AC-12263
AC1L1PY2
Actimoxi
Almodan
alpha-amino-P-Hydroxybenzylpenicillin
alpha-Amino-p-hydroxybenzylpenicillin
Ambap26787-78-0
AMC
Amix
Amoclen
Amolin
Amopen
Amopenixin
Amoram
Amox
Amox 250 cap 250MG
Amox 500 cap 500MG
Amox S 125 sus 125mg/5ML
Amox S 250 sus 250mg/5ML
Amoxi
Amoxibiotic
Amoxicaps
Amoxicilina
Amoxicilina [INN-Spanish]
amoxicillanyl
amoxicillin
Amoxicillin
Amoxicillin (anhydrous)
Amoxicillin (INN)
Amoxicillin (TN)
Amoxicillin and clavulanate potassium
Amoxicillin anhydrous
Amoxicillin clariana brand
AMOXICILLIN CRYSTALLINE
Amoxicillin monopotassium salt
Amoxicillin monosodium salt
Amoxicillin pediatric
AMOXICILLIN PEDIATRIC
Amoxicillin sodium
Amoxicillin trihydrate
Amoxicillin Trihydrate
Amoxicillin(usan)
Amoxicillin, (r*)-isomer
Amoxicilline
Amoxicilline [INN]
Amoxicilline [INN-French]
Amoxicillinum
Amoxicillinum [INN-Latin]
Amoxid
Amoxiden
Amoxil
Amoxi-mast
Amoxi-Mast
Amoxivet
Amoxycilin
Amoxycillin
Amoxycillin trihydrate
Amoxycillin Trihydrate
Amoxycillin, ban
Amoxymed
AMPC
Amrit
Anemolin
Anhydrous, amoxicillin
apo-Amoxi
Apo-Amoxi
apo-Amoxi cap 250MG
apo-Amoxi cap 500MG
apo-Amoxi PWR for susp 125mg/5ML
apo-Amoxi PWR for susp 250mg/5ML
apo-Amoxi sugar free
Aspenil
AUGMENTIN '125'
AUGMENTIN '200'
AUGMENTIN '250'
AUGMENTIN '400'
AUGMENTIN '500'
AUGMENTIN '875'
AUGMENTIN es-600
AX
Biomox
BLP 1410
BL-P 1410
|
BPBio1_000499
BRD-K55044200-001-03-9
Bristamox
BRL 2333
BRL-2333
BSPBio_000453
C06827
Cemoxin
CHEBI:2676
CHEBI:53712
CHEMBL1082
CID33613
Clamoxyl
Clamoxyl (SKB)
Clamoxyl g.a.
Clamoxyl parenteral
Clariana brand OF amoxicillin
CPD000058707
D-(-)-alpha-amino-P-Hydroxybenzyl penicillin
D-(-)-alpha-amino-P-Hydroxybenzylpenicillin
D-(-)-alpha-Amino-p-hydroxybenzylpenicillin
D-(alpha-amino-P-Hydroxybenzyl)penicillin
D07452
D-2-amino-2-(4-Hydroxyphenyl)acetamidopenicillanic acid
D-2-Amino-2-(4-hydroxyphenyl)acetamidopenicillanic acid
D-Amoxicillin
DB01060
Delacillin
Dispermox
DisperMox
Efpenix
EINECS 248-003-8
Flemoxin
G.A., clamoxyl
Galenamox
Gen-amoxicillin 250MG
Gen-amoxicillin 500MG
Hiconcil
Histocillin
HMS1569G15
HSDB 3204
Hydroxyampicillin
Ibiamox
Imacillin
Lamoxy
Larotid
LS-149721
Metafarma capsules
Metifarma capsules
MLS000028632
MLS002222248
MolPort-003-981-182
MolPort-005-933-687
Moxacin
Moxal
Moxatag
NCGC00179554-01
Novamoxin cap 250MG
Novamoxin cap 500MG
Novamoxin sus 125mg/5ML
Novamoxin sus 250mg/5ML
NSC 277174
NSC277174
Nu-amoxi cap 250MG
Nu-amoxi cap 500MG
Nu-amoxi sus 125/5ML
Nu-amoxi sus 250mg/5ML
Ospamox
Pamoxicillin
Parenteral, clamoxyl
Penamox
Pfizer brand OF amoxicillin sodium salt
PHL-Amoxicillin
p-Hydroxyampicillin
P-Hydroxyampicillin
Piramox
PMS-Amoxicillin
Polymox
Prestwick_713
Prestwick0_000357
Prestwick1_000357
Prestwick2_000357
Prestwick3_000357
Prevpac
pro Amox PWR for oral susp 125mg/5ML
pro Amox-250 cap 250MG
pro Amox-500 cap 500MG
pro-Amox-250 orl sus 250mg/5ML
R-Hydroxyampicillin
Rimoxallin
Ro 10-8756
Robamox
SAM002264592
Sauracillin
Sawamox PM
SmithKline beecham brand OF amoxicillin sodium salt
SMR000058707
Sodium, amoxicillin
SPBio_002374
Sumox
Tolodina
Trihydrate, amoxicillin
Trimox
Unicillin
Utimox
Vetramox
Wymox
Zimox
α-amino-p-hydroxybenzylpenicillin
α-amino-P-hydroxybenzylpenicillin
|
|
| 30 |
|
Levofloxacin |
Approved, Investigational |
Phase 3 |
|
100986-85-4 |
149096
|
|
Synonyms:
(−
(-)-(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7Hpyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-(S)-9-fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyridol[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid hemihydrate
(-)-Ofloxacin
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylate
(3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid
(3S)-9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
(R)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(R)-isomer
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylate
(S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-9-fluoro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid
(S)-(-)-Ofloxacin
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylate
(S)-9-fluoro-2,3-dihydro-3-Methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(S)-Ofloxacin
)-Ofloxacin
100986-85-4
100986-86-5
28266_FLUKA
28266_SIGMA
AC1L3YF8
AC-7593
Aeroquin
Ambap100986-85-4
Anhydrous, levofloxacin
BRD-K09471561-001-06-7
BSPBio_002689
C07660
C18H20FN3O4
C18H20FN3O4.H2O
CCRIS 4073
CCRIS 4074
CHEMBL33
CID149096
CPD000466387
Cravit
Cravit (TN)
Cravit Ophthalmic
D08120
DB01137
d-Levofloxacin
DR 3354
DR3355
DR-3355
DR-3355: L-isomer of ofloxacin
Elequine
Floxacin
Floxel
Floxin
HMS1922J07
HMS2051G04
HMS2090O10
HMS2093E18
HR 355
HR-355
Iquix
KBio2_002199
|
KBio2_004767
KBio2_007335
KBio3_001909
KBioGR_001605
KBioSS_002199
L0193
Leroxacin
Lesacin
Levaquin
LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER
LEVOFLOXACIN
Levofloxacin (INN)
Levofloxacin [USAN:INN:JAN]
Levofloxacin anhydrous
Levofloxacin hydrate
Levofloxacin tablet, suspension or intravenous
Levofloxacine
Levofloxacine [INN-French]
Levofloxacino
Levofloxacino [INN-Spanish]
Levofloxacinum
Levofloxacinum [INN-Latin]
Levokacin
Levox
Levoxacin
LFX
L-Ofloxacin
LS-133260
LS-171761
LVX
MLS000759524
MLS001165709
MLS001423977
MolPort-002-885-835
Mosardal
MP-376
NCGC00178529-01
Nofaxin
Ofloxacin
Ofloxacin S-(-)-form
Ofloxacin, (S)-isomer
Oftaquix
Quixin
Reskuin
R-Ofloxacin
RWJ 25213-097
RWJ-25213
S-(-)-Ofloxacin
S1940_Selleck
SAM001246758
SMR000466387
SPBio_001891
Spectrum_001719
SPECTRUM1504260
Spectrum2_001676
Spectrum3_000995
Spectrum4_001123
Spectrum5_001438
Tavanic
Volequin
|
|
| 31 |
|
Ofloxacin |
Approved |
Phase 3 |
|
82419-36-1 |
4583
|
|
Synonyms:
( -)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure
(+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7- -oxo-7H-pyrido(1,2,3-de)- -1,4-benzoxazine-6-carboxylic acid
(+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid
(+/-)-Floxin
118120-51-7 (hydrochloride)
33703_FLUKA
33703_RIEDEL
82419-36-1
83380-47-6
85344-55-4
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylate
8-fluoro-3-Methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
8-Fluoro-3-methyl-9-(4-methyl-piperazin-1-yl)-6-oxo-2,3-dihydro-6H-1-oxa-3a-aza-phenalene-5-carboxylic acid
9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
AB00513820
AC1L1IHM
AC-7616
AKOS001033517
Bactocin
BB_SC-1252
BPBio1_000345
BRD-A24228527-001-05-9
BRN 3657947
BSPBio_000313
BSPBio_003117
C07321
C18H20FN3O4
CCRIS 5233
CHEBI:7731
CHEMBL4
CID4583
CPD000058192
D00453
Danoflox
DB01165
DEXTROFLOXACINE
DivK1c_000721
DL 8280
DL-8280
DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin
Effexin
EU-0100904
Exocin
Exocine
Flobacin
Flodemex
Flotavid
Flovid
Floxal
Floxil
Floxin
Floxin (TN)
FLOXIN IN DEXTROSE 5%
FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Floxin otic
Floxstat
Fugacin
HMS1568P15
HMS1921H12
HMS2090F07
HMS2092B10
HMS502E03
Hoe 280
HOE 280
Hoe-280
I06-0112
I06-0380
IDI1_000721
Inoflox
KBio1_000721
KBio2_001666
KBio2_004234
KBio2_006802
KBio3_002617
KBioGR_000667
KBioSS_001666
Kinflocin
Kinoxacin
Liflox
Lopac0_000904
Loxinter
LS-133259
Marfloxacin
Medofloxine
Mergexin
MLS000028749
MLS001074203
MolPort-000-422-241
MolPort-000-873-068
NCGC00015772-02
NCGC00015772-10
|
NCGC00094219-01
NCGC00094219-02
NCGC00094219-03
NCGC00094219-04
NCGC00094219-05
NCGC00094219-06
NCGC00178284-01
NCGC00178284-02
NINDS_000721
Novecin
NSC727071
Nufafloqo
O 8757
O8757_SIGMA
Obide
Occidal
Ocuflox
Ofcin
Oflin
Oflocee
Oflocet
Oflocin
Oflodal
Oflodex
Oflodura
Oflox
O-Flox
ofloxacin
Ofloxacin (JP15/USP/INN)
Ofloxacin [USAN:BAN:INN:JAN]
Ofloxacin hydrochloride
Ofloxacin Otic
Ofloxacin, (S)-Isomer
Ofloxacina
Ofloxacina [DCIT]
Ofloxacine
Ofloxacine [French]
Ofloxacino
Ofloxacino [Spanish]
Ofloxacinum
Ofloxacinum [Latin]
Ofloxin
OFLX
Ofus
OFX
Onexacin
Operan
Oprea1_242882
ORF 18489
ORF-28489
Orocin
Otonil
Oxaldin
Pharflox
Praxin
Prestwick0_000237
Prestwick1_000237
Prestwick2_000237
Prestwick3_000237
PT 01
Puiritol
Qinolon
Qipro
Quinolon
Quotavil
Rilox
Ru-43280
S1463_Selleck
SAM002264629
Sinflo
SMR000058192
SPBio_001387
SPBio_002234
Spectrum_001186
SPECTRUM1502044
Spectrum2_001464
Spectrum3_001499
Spectrum4_000324
Spectrum5_001063
STK256723
Tabrin
Taravid
Tariflox
Tarivid
Telbit
Tructum
UNII-A4P49JAZ9H
Uro Tarivid
Viotisone
Visiren
WP-0405
XED
Zanocin
|
|
| 32 |
|
Cefepime |
Approved, Investigational |
Phase 3,Phase 1 |
|
88040-23-7 |
5479537
|
|
Synonyms:
(6R,7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-3-[(1-methylpyrrolidin-1-ium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate
(6R,7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-3-[(1-methylpyrrolidinium-1-yl)methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
1-(((6R,7R)-7-(2-(2-Amino-4-thiazolyl)glyoxylamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-en-3-yl)methyl)-1-methylpyrrolidinium hydroxide, inner salt, 7(sup 2)-(Z)-(O-methyloxime)
7beta-[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido]-3-[(1-methylpyrrolidinium-1-yl)methyl]-3,4-didehydrocepham-4-carboxylate
88040-23-7
AC1NUIFH
Axepim
Axépim
BMY 28142
BMY-28142
Bristol-myers brand OF cefepime dihydrochloride
Bristol-myers squibb brand OF cefepime dihydrochloride
C08111
C19H24N6O5S2
Cefepim
Cefepima
Cefepima [Spanish]
cefepime
Cefepime
Cefepime (USAN/INN)
|
Cefepime [USAN:INN]
Cefepime hydrochloride
Cefepimum
Cefepimum [Latin]
Cepimax
Cepimex
CFPM
CHEBI:478164
CHEMBL186
CID5479537
D02376
DB01413
Elan brand OF cefepime dihydrochloride
HMS2089M18
LS-178033
Maxcef
Maxipime
Quadrocef
UNII-807PW4VQE3
ZINC03871924
|
|
| 33 |
|
Miconazole |
Approved, Investigational, Vet_approved |
Phase 3,Phase 2,Phase 1,Not Applicable |
|
22916-47-8 |
4189
|
|
Synonyms:
(+-)-1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-(2,4-dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl) imidazole
1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole
1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole
1-[2-(2,4-Dichloro-benzyloxy)-2-(2,4-dichloro-phenyl)-ethyl]-1H-imidazole
1-[2-(2,4-Dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]-1H-imidazole
1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole
1-[2-(2,4-dichlorophenyl)-2-{[(2,4-dichlorophenyl)methyl]oxy}ethyl]-1H-imidazole
1-[2,4-Dichloro- beta-([2,4-dichloro- benzyl]oxy)phenethyl]imidazole
1-{2-[(2,4-dichlorobenzyl)oxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole
22832-87-7 (NITRATE)
22916-47-8
75319-47-0
AB00053500
AC1L1HM1
Aflorix(nitrate)
AKOS001574474
Albistat(nitrate)
Andergin(nitrate)
BPBio1_000279
BRD-A82396632-001-03-0
BRD-A82396632-008-02-7
Brentan
BRN 0965511
BSPBio_000253
BSPBio_002033
CCRIS 7924
CHEBI:6923
CHEMBL91
CID4189
Conofite(nitrate)
CPD-4501
D00416
Dactarin
Daktarin iv
Daktarin IV
DB01110
DivK1c_000156
EINECS 245-324-5
Epi-Monistat(nitrate)
Esteve brand OF miconazole
Femizol-M
Florid(nitrate)
Gyno-Daktar(nitrate)
HMS1568M15
HMS2090B21
I14-14342
IDI1_000156
imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl) methoxy)ethyl)- (9CI)
Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((2,4-dichlorophenyl)methoxy)ethyl)- (9CI)
Janssen cilag brand OF miconazole
Janssen-cilag brand OF miconazole
Johnston and johnston brand OF miconazole nitrate
KBio1_000156
KBio2_001445
KBio2_004013
KBio2_006581
KBio3_001533
KBioGR_000581
KBioSS_001445
Lotrimin AF(nitrate)
LS-78378
MCZ
Micantin (nitrate)
Miconasil nitrate
Miconasil Nitrate
Miconazol
|
Miconazol [INN-Spanish]
miconazole
Miconazole
Miconazole (JP15/USP/INN)
Miconazole [USAN:BAN:INN:JAN]
Miconazole 3
Miconazole 3 Combination Pack
Miconazole 7 Combination Pack
Miconazole esteve brand
Miconazole janssen-cilag brand
Miconazole nitrate
Miconazole nitrate salt
Miconazole-7
Miconazolo
Miconazolo [DCIT]
Miconazolum
Miconazolum [INN-Latin]
Micozole
Minostate
MJR 1762
MLS002222203
MolPort-002-557-553
Monazole 7
Monista (nitrate)
Monistat
Monistat (TN)
Monistat 1 Combination Pack
Monistat 3 Dual-Pak
Monistat 3 Vaginal Ovules
Monistat 5 Tampon
Monistat 7 Dual-Pak
Monistat 7 Vaginal Suppositories
Monistat Dual- PAK
Monistat IV
Monistat iv (tn)
Monistat iv (TN)
Monistat-Derm
NCI60_001353
NCI60_001380
NINDS_000156
Nitrate, miconasil
Nitrate, miconazole
Novo-Miconazole Vaginal Ovules
NSC 170986
NSC169434
NSC170986
Oprea1_091955
Prestwick_335
Prestwick0_000067
Prestwick1_000067
Prestwick2_000067
Prestwick3_000067
R 18134
R-14,889
SMR001307249
SPBio_000976
SPBio_002174
Spectrum_000965
Spectrum2_001048
Spectrum3_000507
Spectrum4_000061
Spectrum5_001297
STK834405
STOCK1S-93556
UNII-7NNO0D7S5M
Vusion
Zimycan
|
|
| 34 |
|
Melphalan |
Approved |
Phase 2, Phase 3,Phase 1,Not Applicable |
|
148-82-3 |
4053
460612
|
|
Synonyms:
(2s)-2-amino-3-(4-[bis(2-chloroethyl)amino]phenyl)propanoic acid
(2S)-2-amino-3-[4-[bis(2-chloroethyl)amino]phenyl]propanoic acid
148-82-3
3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
3-(p-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3-(P-(Bis(2-chloroethyl)amino)phenyl)-L-alanine
3025 c.b
3025 C.B.
3223-07-2
3-p-(Di(2-chloroethyl)amino)-phenyl-L-alanine
3-P-(Di(2-chloroethyl)amino)-phenyl-L-alanine
4-(Bis(2-chloroethyl)amino)-L-phenylalanine
4-(Bis(2-chloroethyl)amino)phenylalanine
4-[Bis(2-chloroethyl)amino]-L-phenylalanine
4-[Bis-(2-chloroethyl)amino]-L-phenylalanine
4-14-00-01689 (Beilstein Handbook Reference)
AC1LA2OE
Alanine Nitrogen Mustard
Alkeran
ALKERAN (TN)
AmbotzHAA1563
At-290
AY3360000
BIDD:GT0044
BRD-K87827419-001-02-8
BRN 2816456
BSPBio_002407
C13H18Cl2N2O2
CB 3025
CB-3025
CCRIS 374
CHEBI:165415
CHEBI:28876
CHEMBL852
CID460612
D00369
DivK1c_000653
EINECS 205-726-3
HMS2090B09
HMS2091B16
HMS502A15
HSDB 3234
IDI1_000653
KBio1_000653
KBio2_000877
KBio2_003445
KBio2_006013
KBio3_001627
KBioGR_001284
KBioSS_000877
L-3-(p-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(P-(Bis(2-chloroethyl)amino)phenyl)alanine
L-3-(para-(Bis(2-chloroethyl)amino)phenyl)alanine
Levofalan
Levofolan
Levopholan
L-PAM
L-Phenylalanine mustard
LS-15868
LS-865
L-Sarcolysin
L-Sarcolysine
L-Sarkolysin
M2011_SIGMA
|
Medphalan
Melfalan
Melfalano
Melfalano [INN-Spanish]
melphalan
Melphalan (JP15/USP/INN)
MELPHALAN (SEE ALSO TRANSGENIC MODEL EVALUATION (MELPHALAN))
Melphalan [USAN:INN:BAN:JAN]
Melphalanum
Melphalanum [INN-Latin]
Mephalan
Merphalan
MLS001333666
MLS002153368
MolPort-003-665-535
Mustard, phenylalanine
NCGC00090757-01
NCGC00090757-02
NCGC00090757-03
NCI-C04853
NINDS_000653
NIOSH/AY3360000
NSC 241286
NSC 8806
NSC241286
NSC8806
NSC-8806
P-Bis(b-chloroethyl)aminophenylalanine
p-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(beta-chloroethyl)aminophenylalanine
P-Bis(β-chloroethyl)aminophenylalanine
p-Di-(2-chloroethyl)amino-L-phenylalanine
P-Di-(2-chloroethyl)amino-L-phenylalanine
Phenylalanine mustard
phenylalanine nitrogen mu stard
Phenylalanine nitrogen mustard
p-L-Sarcolysin
P-L-Sarcolysin
p-L-sarcolysine
p-N,N-bis(2-chloroethyl)amino-L-phenylalanine
P-N,N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-Bis(2-chloroethyl)amino-L-phenylalanine
P-N-Bis(2-chloroethyl)amino-L-phenylalanine
p-N-di(chloroethyl)aminophenylala nine
p-N-Di(chloroethyl)aminophenylalanine
Prestwick_1006
RCRA waste no. U150
Rcra waste number U150
Sarcolysine
Sarkolysin
SK-15673
SMP2_000174
SMR000058720
SPBio_000287
Spectrum_000397
SPECTRUM1500382
Spectrum2_000074
Spectrum3_000684
Spectrum4_000882
Spectrum5_001601
TL8001065
TRANSGENIC LEP (MELPHALAN) (SEE ALSO MELPHALAN)
TRANSGENIC MODEL EVALUATION (MELPHALAN)
UNII-Q41OR9510P
|
|
| 35 |
|
Fludarabine |
Approved |
Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable |
|
75607-67-9, 21679-14-1 |
30751
|
|
Synonyms:
(2R,3S,4S,5R)-2-(6-amino-2-fluoro-9H-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
(2R,3S,4S,5R)-2-(6-amino-2-fluoropurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
21679-14-1
2-F-ara-A
2-F-ARAA
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoro Ara-A
2-Fluoro-9-beta-D-arabinofuranosyladenine
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-fluoro-ARA AMP
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-arabinofuranosyl-2-fluoro-9H-purin-6-amine
9-beta-D-Arabinofuranosyl-2-fluoroadenine
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9H-Purin-6-amine, 9-beta-D-arabinofuranosyl-2-fluoro- (9CI)
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-β-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-β-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
AC1LCW8I
AC1Q51CF
Beneflur
C10H12FN5O4
CCRIS 3382
CHEMBL1568
CID657237
|
CPD000058874
D07966
EINECS 244-525-5
FAMP
FaraA
F-Ara-A
FaraAMP
F-Ara-AMP
Fludara
Fludara, Fludarabine
Fludarabina
Fludarabina [Spanish]
Fludarabine
Fludarabine (INN)
Fludarabine [INN]
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabinum
Fludarabinum [Latin]
Fludura
fluoro-Ara-AMP
Fluradosa
Fluradosa (TN)
FT-0082766
HSDB 6964
I14-4978
LS-15061
MLS000028687
NSC 118218
NSC 118218H
NSC-118218
S1491_Selleck
SAM002548956
SMR000058874
SQ Fludarabine
UNII-1X9VK9O1SC
UNII-P2K93U8740
ZINC04216238
|
|
| 36 |
|
Etoposide |
Approved |
Phase 2, Phase 3,Phase 3,Phase 1,Early Phase 1,Not Applicable |
|
33419-42-0 |
36462
|
|
Synonyms:
(−)-etoposide
(-)-Etoposide
121471-01-0
136598-18-0
201594-04-9
33419-42-0
35317-32-9
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-b-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-β-D-glucopyranoside)
4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside
4-Demethylepipodophyllotoxin b-D-ethylideneglucoside
4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside
4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside
4-demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin β-D-ethylideneglucoside
4-Demethylepipodophyllotoxin-.beta.-D-ethylideneglucoside
4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin
51854-34-3
76576-58-4
9-((4,6-O-Ethylidine-b-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one
9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
9-((4,6-O-Ethylidine-β-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-D)-1,3-dioxol-6(5ah)-one
AB00438905
AC1L1FN8
AC1L1VT3
AC1L6246
AC1NR4OG
AC1O4WGG
AC1O7M1N
AC1Q47JJ
alpha-D-Glucopyranosyl isomer etoposide
Ambap33419-42-0
Baxter brand OF etoposide
Baxter oncology brand OF etoposide
Bio1_000489
Bio1_000978
Bio1_001467
BPBio1_000673
BRD-K37798499-001-02-5
Bristol myers brand OF etoposide
Bristol myers squibb brand OF etoposide
Bristol-myers brand OF etoposide
Bristol-myers squibb brand OF etoposide
BSPBio_000611
C01576
CCRIS 2392
Celltop
CHEBI:4911
CHEBI:588795
CHEMBL44657
CID11758093
CID284997
CID3310
CID36462
CID5284558
CID6419930
CID6610299
CPD000112002
D00125
DB00773
DEMETHY-EPIPODOPHYLLOTOXIN,ETHYLIDENE GLUCOSIDE,
Demethyl epipodophyllotoxin ethylidine glucoside
Demethyl Epipodophyllotoxin Ethylidine Glucoside
Demethyl-epiodophyllotoxin ethylidene glucoside
Demethylepipodophyllotoxin-beta-D-ethylideneglucoside
E0675
E1383_SIGMA
EINECS 251-509-1
Epipodophyllotoxin VP-16213
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-.beta.-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside
Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside (8CI)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-.beta.-D-glucopyranoside)
Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside)
Eposide
Eposin
Eposin, Vepesid, VP-16, Toposar, Etoposide
eto GRY
eto-GRY
Etomedac
ETOP
Etopol
Etopophos
Etopophos (phosphate salt)
Etopos
|
etoposide
Etoposide (JP15/USP/INN)
Etoposide (VP16)
Etoposide [USAN:INN:BAN:JAN]
Etoposide pierre fabre
Etoposide teva
Etoposide, (5a alpha)-isomer
Etoposide, (5a alpha,9 alpha)-isomer
Etoposide, (5S)-isomer
Etoposide, alpha D glucopyranosyl isomer
Etoposide, alpha-D-glucopyranosyl isomer
Etoposido
Etoposido [INN-Spanish]
etoposido Ferrer farma
Etoposidum
Etoposidum [INN-Latin]
Etosid
Exitop
Ferrer brand OF etoposide
Gry brand OF etoposide
HMS1569O13
HMS2052N05
HMS2089F14
HSDB 6517
I06-0248
KBioSS_002410
Lastet
Lemery brand OF etoposide
LS-1214
Medac brand OF etoposide
MLS000049957
MLS001074951
MLS001424283
MLS002153463
MLS002207239
MLS002222184
MolPort-003-983-431
MolPort-004-905-001
MolPort-004-955-161
NCGC00025056-02
NChemBio.2007.10-comp19
nchembio.573-comp8
nchembio873-comp2
NK 171
Novartis brand OF etoposide
NSC 141540
NSC141540
NSC-141540
Onkoposid
Onkoworks brand OF etoposide
Pharmachemie brand OF etoposide
Pierre fabre brand OF etoposide
Prasfarma brand OF etoposide
Prestwick_211
Prestwick0_000396
Prestwick1_000396
Prestwick2_000396
Prestwick3_000396
Riboposid
Ribosepharm brand OF etoposide
S1225_Selleck
SAM001246880
Sanfer brand OF etoposide
SMR000112002
SPBio_002532
ST056353
Tedec meiji brand OF etoposide
Teva brand OF etoposide
Toposar
trans-Etoposide
UNII-6PLQ3CP4P3
Vepesid
VePesid
VePESID (TN)
Vepesid J
Vepeside
Vépéside sandoz
Vépéside-sandoz
VP 16
VP 16 (pharmaceutical)
VP 16213
VP 16-213
VP-16
VP-16-213
ZINC03830818
ZINC03938684
Zuyeyidal
|
|
| 37 |
|
Doxorubicin |
Approved, Investigational |
Phase 2, Phase 3,Phase 1,Not Applicable |
|
23214-92-8 |
31703
|
|
Synonyms:
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-a-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
(1S,3S)-3-Glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-α-L-lyxo-hexopyranoside
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-a-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
(8S-cis)-10-((3-amino-2,3,6-Trideoxy-α-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
111266-55-8
14-hydroxydaunomycin
14-Hydroxydaunomycin
14-hydroxydaunorubicine
14-Hydroxydaunorubicine
23214-92-8
23257-17-2
24385-08-8
25311-50-6
25316-40-9
25316-40-9 (hydrochloride)
29042-30-6
AC1L1M5T
AC1Q29OJ
adiblastine (hydrochloride salt)
ADM
ADR
adr iablatina (hydrochloride salt)
Adriablastin
Adriablastine
adriablastine (hydrochloride salt)
adriablatina (hydrochloride salt)
Adriacin (hydrochloride salt)
Adriamycin
Adriamycin PFS
Adriamycin PFS (hydrochloride salt)
Adriamycin RDF
Adriamycin RDF (hydrochloride salt)
Adriamycin semiquinone
Adriamycin Semiquinone
Adriblas tina
Adriblastin
Adriblastina
Adriblastina (hydrochloride salt)
Adriblastina (TN)
Adriblastine
adriblatina (hydrochloride salt)
Adrimedac
Aerosolized Doxorubicin
Baxter brand OF doxorubicin hydrochloride
Bedford brand OF doxorubicin hydrochloride
BPBio1_000502
BRD-K92093830-003-04-3
Bristol-myers squibb brand OF doxorubicin hydrochloride
BSPBio_000456
BSPBio_001031
C01661
C27H29NO11
Caelyx
CCRIS 739
Cell pharm brand OF doxorubicin hydrochloride
CHEBI:28748
CHEMBL179
CID31703
Columbia brand OF doxorubicin hydrochloride
Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74
Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120
D03899
DB00997
DM2
Doxil
Doxo
doxo Cell
doxo-Cell
Doxolem
doxorubicin
Doxorubicin
Doxorubicin (USAN/INN)
Doxorubicin [USAN:INN:BAN]
Doxorubicin citrate
Doxorubicin HCl
|
Doxorubicin hexal
Doxorubicin hydrochloride
Doxorubicin Hydrochloride
Doxorubicin hydrochloride (hydrochloride salt)
Doxorubicin NC
Doxorubicina
Doxorubicina [INN-Spanish]
Doxorubicina ferrer farm
Doxorubicina funk
Doxorubicina tedec
Doxorubicine
Doxorubicine [INN-French]
Doxorubicine baxter
Doxorubicin-hLL1
Doxorubicin-hLL1 conjugate
Doxorubicin-P4/D10
Doxorubicin-P4/D10 conjugate
Doxorubicinum
Doxorubicinum [INN-Latin]
Doxotec
DOX-SL
EINECS 245-495-6
Elan brand OF doxorubicin hydrochloride
Farmablastina (hydrochloride salt)
Farmiblastina
Ferrer brand OF doxorubicin hydrochloride
FI 106
Hexal brand OF doxorubicin hydrochloride
HMS2089H06
HSDB 3070
Hydrochloride, doxorubicin
Hydroxydaunomycin hydrochlor ide (hydrochloride salt)
Hydroxydaunomycin hydrochloride (hydrochloride salt)
Hydroxydaunorubicin
Hydroxydaunorubicin hydrochloride (hydrochloride salt)
JT9100000
Kenfarma brand OF doxorubicin hydrochloride
Lemery brand OF doxorubicin hydrochloride
LMPK13050001
LS-1029
LS-165655
Medac brand OF doxorubicin hydrochloride
MLS000759533
Myocet
NChemBio.2007.10-comp13
nchembio809-comp5
NCI-C01514
NDC 38242-874
Neocorp brand OF doxorubicin hydrochloride
NIOSH/JT9100000
NSC 123127
Onkodox
Onkoworks brand OF doxorubicin hydrochloride
Pfizer brand OF doxorubicin hydrochloride
Prasfarma brand OF doxorubicin hydrochloride
Prestwick0_000438
Prestwick1_000438
Prestwick2_000438
Prestwick3_000438
Probes1_000151
Probes2_000129
RDF Rubex
Resmycin
Ribodoxo
Ribosepharm brand OF doxorubicin hydrochloride
Rubex
Rubex (hydrochloride salt)
SMP1_000106
SPBio_002395
Tedec meiji brand OF doxorubicin hydrochloride
ThermoDox
TLC D-99
Triferric doxorubicin
UNII-80168379AG
Urokit doxo cell
Urokit doxo-cell
|
|
| 38 |
|
Panobinostat |
Approved, Investigational |
Phase 2, Phase 3,Phase 3,Phase 1 |
|
404950-80-7 |
6918837
|
|
Synonyms:
(2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide
(E)-N-HYDROXY-3-(4-{[2-(2-METHYL-1H-INDOL-3-YL)-ETHYLAMINO]-METHYL}-PHENYL)-ACRYLAMIDE
(E)-N-hydroxy-3-[4-[[2-(2-methyl-1H-indol-3-yl)ethylamino]methyl]phenyl]prop-2-enamide
404950-80-7
AC1OCFY8
AKOS005146046
C496932
CHEMBL483254
CID6918837
EC-000.2287
Faridak
FT-0083488
LBH 589
|
LBH589
LBH-589
LBH-589B
MolPort-005-933-338
nchembio.313-comp11
NVP-LBH589
NVP-LBH-589
panobinostat
Panobinostat
Panobinostat, NVP-LBH589, LBH589
S1030_Selleck
ZINC22010649
|
|
| 39 |
|
Iron |
Approved |
Phase 3,Phase 2,Phase 1,Not Applicable |
|
7439-89-6 |
23925
|
|
Synonyms:
02583_FLUKA
12310_ALDRICH
12310_RIEDEL
129048-51-7
14067-02-8
161135-39-3
190454-13-8
195161-83-2
199281-22-6
209309_ALDRICH
209309_SIAL
255637_ALDRICH
266213_ALDRICH
266256_ALDRICH
267945_ALDRICH
267953_ALDRICH
26Fe
338141_ALDRICH
356808_ALDRICH
356824_ALDRICH
356832_ALDRICH
39344-71-3
3ZhP
413054_ALDRICH
443783-52-6
44890_ALDRICH
44890_FLUKA
675141-17-0
70884-35-4
73135-38-3
7439-89-6
8011-79-8
8053-60-9
AC1L2N38
Ancor B
Ancor en 80/150
armco Iron
Armco iron
Atomel 28
Atomel 300M200
Atomel 500M
Atomel 95
Atomiron 44MR
Atomiron 5M
Atomiron AFP 25
Atomiron AFP 5
ATW 230
ATW 432
C00023
C3518_SIAL
C3518_SIGMA
Carbonyl iron
CCRIS 1580
CHEBI:18248
CID23925
Copy Powder CS 105-175
D007501
DB01592
Diseases (animal), iron overload
Diseases, iron overload
DSP 1000
DSP 128B
DSP 135
DSP 135C
DSP 138
Ed-In-Sol
EF 1000
EF 250
EFV 200/300
EFV 250
EFV 250/400
EINECS 231-096-4
Eisen
Electrolytic iron
F 60 (metal)
Fe
FE
FE (II) ion
Fe(2+)
Fe(II)
Fe1+
|
Fe-40
fer
Feronate
Ferretts
Ferro-Caps
Ferro-Time
Ferrous ion
ferrous iron
Ferrousal
Ferrovac e
Ferrovac E
Ferrum
Ferrum metallicum
FT 3 (element)
GS 6
Hematite
Hemocyte
HF 2 (element)
hierro
Hierro
HL (iron)
Hoeganaes ATW 230
Hoeganaes EH
HQ (metal)
HS (iron)
HS 4849
HSDB 604
Infed
IRMM524A_FLUKA
IRMM524B_FLUKA
IRON
Iron (Fe)
Iron (Fe1+)
Iron ion (Fe+)
Iron ion(1+)
Iron ion(2+)
Iron monocation
Iron powder
Iron standard for AAS
Iron(1+)
Iron(1+) ion
Iron(III) nitrate solution
Iron, carbonyl
Iron, electrolytic
Iron, elemental
Iron, ion (Fe1+)
Iron, ion (Fe1+) (8CI,9CI)
Iron, reduced
Limonite
LOHA
LS-3196
Magnetite
Malleable iron
Metopirone
Metyrapone
MolPort-003-925-001
NC 100
PZh1M1
PZh-1M3
PZh-2
PZh2M
PZH2m
PZh2M1
PZh2M2
PZh3
PZh3M
PZh4M
PZhO
PZHO
Reduced iron
Remko
Siderol
Suy-b 2
SUY-B 2
Taconite
UNII-E1UOL152H7
Venofer
Vitedyn-Slo
Wrought iron
Yieronia
|
|
| 40 |
|
Darbepoetin alfa |
Approved, Investigational |
Phase 3,Phase 2 |
|
11096-26-7, 209810-58-2 |
|
|
Synonyms:
|
|
Darbepoetin alfa,recombinant
|
|
| 41 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 3 |
|
437-38-7 |
3345
|
|
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-phenethyl-4-N-propionylanilinopiperidine
1-Phenethyl-4-N-propionylanilinopiperidine
437-38-7
5-22-08-00049 (Beilstein Handbook Reference)
80832-90-2
990-73-8 (citrate)
AC1L1FQ2
Actiq
BIDD:GT0555
BRN 0494484
Cephalon brand OF fentanyl buccal oravescent
CHEBI:119915
CHEMBL596
CID3345
D00320
DB00813
Duragesic
Duragesic (TN)
Duragesic-100
Duragesic-12
Duragesic-25
Duragesic-50
Duragesic-75
Durogesic
EINECS 207-113-6
Fentanest
Fentanil
Fentanil [DCIT]
Fentanila
Fentanila [INN-Spanish]
Fentanilo
fentanyl
Fentanyl
Fentanyl (JAN/USAN/INN)
Fentanyl [INN:BAN]
Fentanyl CII
Fentanyl citrate
Fentanyl-100
Fentanyl-12
Fentanyl-25
Fentanyl-50
|
Fentanyl-75
Fentanylum
Fentanylum [INN-Latin]
Fentora
HSDB 3329
IONSYS
Janssen pharmaceutica brand OF fentanyl
JNS020QD
L001275
LS-124439
Matrifen
MolPort-003-847-369
N-(1-phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-phenethyl-4-piperidyl)propionanilide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropanamide
N-(1-phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
Nasalfent
NCGC00168252-01
N-phenethyl-4-(N-propionylanilino)piperidine
N-Phenethyl-4-(N-propionylanilino)piperidine
N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]propanamide
Oprea1_152073
Oprea1_207148
PDSP1_000860
PDSP2_000846
Pentanyl
Phentanyl
Propanamide, N-phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)- (9CI)
R 4263
Rapinyl
Sentonil
Sublimase
Sublimaze
Transmucosal oral fentanyl citrate
UNII-UF599785JZ
|
|
| 42 |
|
Caspofungin |
Approved |
Phase 3,Phase 2 |
|
179463-17-3, 162808-62-0 |
468682
2826718
|
|
Synonyms:
(4R,5S)-5-((2-aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
(4R,5S)-5-((2-Aminoethyl)amino)-N(2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(P-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
(4R,5S)-5-((2-Aminoethyl)amino)-N(sup 2)-(10,12-dimethyltetradecanoyl)-4-hydroxy-L-ornithyl-L-threonyl-trans-4-hydroxy-L-prolyl-(S)-4-hydroxy-4-(p-hydroxyphenyl)-L-threonyl-threo-3-hydroxy-L-ornithyl-trans-3-hydroxy-L-proline cyclic (6-1)-peptide
[1(R)-hydroxyethyl]-1,4,7,13,16,22-hexaazatricyclo[22.3.0.0(9,13)]heptacosane-2,5,8,14,17,23-hexaone diacetate
1-[(4R,5S)-5-[(2-aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N(2)-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin b0
162808-62-0
AC1L45LR
AC1LAHR5
AC1MCVUN
AR-1K4318
Cancidas
Cancidas (TM)
Cancidas (TN)
Capsofungin
CASPO
Caspofungin
Caspofungin (INN)
Caspofungin [INN]
Caspofungin acetate
Caspofungin MSD
|
CHEBI:474180
CHEMBL374999
CHEMBL499808
CID151068
CID2826718
CID468682
D07626
DB00520
HSDB 7476
L-743,872
LS-186994
LS-187303
LS-187635
M991
MK-0991
n-{(2r,6s,9s,11r,12s,14as,15s,20s,23s,25as)-12-[(2-aminoethyl)amino]-20-[(1r)-3-amino-1-hydroxypropyl]-23-[(1s,2s)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1r)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1h-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
N-{(2R,6S,9S,11R,12S,14aS,15S,20S,23S,25aS)-12-[(2-aminoethyl)amino]-20-[(1R)-3-amino-1-hydroxypropyl]-23-[(1S2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-2,11,15-trihydroxy-6-[(1R)-1-hydroxyethyl]-5,8,14,19,22,25-hexaoxotetracosahydro-1H-dipyrrolo[2,1-c:2',1'-l][1,4,7,10,13,16]hexaazacyclohenicosin-9-yl}-10,12-dimethyltetradecanamide
nchembio.184-comp7
Pneumocandin B0, 1-[(4R,5S)-5-[(2-aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]- (9CI)
UNII-F0XDI6ZL63
|
|
| 43 |
|
Amphotericin B |
Approved, Investigational |
Phase 3 |
|
1397-89-3 |
5280965
14956
|
|
Synonyms:
12633-72-6
1397-89-3
30782-62-8
5-18-10-00525 (Beilstein Handbook Reference)
54482-28-9
8055-20-7
AB00513832
Abelcet
Abelecet
ABLC
AC1L1CN2
AC1L24V6
AC1L70KF
AC1L73U6
AC1NQXTD
AC1NTQ32
AC1NUQG4
AC1NY9JC
AC1O7GCZ
AC1O8FQV
AC1O8PFK
AI3-26528
Ambap1397-89-3
Ambisome
AmBisome (TN)
Amfotericina b
Amfotericina B
Amfotericina B [INN-Spanish]
amophotericin B
AMPH-b
AMPH-B
Amphocil
Amphocin
Amphomoronal
Ampho-Moronal
Amphortericin b
Amphortericin B
Amphotec
Amphotec (TN)
Amphotericin
Amphotericin .BETA.
amphotericin b
Amphotericin B
Amphotericin B (JP15/USP/INN)
Amphotericin B [USAN:INN:JAN]
Amphotericin b cholesterol dispersion
Amphotericin B Cholesterol Dispersion
Amphotericin b colloidal dispersion
Amphotericin B Colloidal Dispersion
amphotericin B liposomal
Amphotericin B, Lipid-based
Amphotericin B, Streptomyces sp.
Amphotericin-B
Amphotericine b
Amphotericine B
Amphotéricine B
Amphotericine B [INN-French]
Amphotericinum
Amphotericinum b
Amphotericinum B
Amphotericinum B [INN-Latin]
Amphotherizin
Amphotherizin [German]
Amphozone
BIDD:GT0351
BPBio1_000374
BRN 0078342
BSPBio_000340
C06573
C47H73NO17
C-AmB
CCRIS 5963
CHEBI:2682
CHEMBL1200646
|
CHEMBL267345
CID10533925
CID10629638
CID10677275
CID14956
CID1972
CID352546
CID354192
CID5280965
CID5386092
CID5458486
CID5771695
CID6604295
CID6708817
CID6713692
CID9919339
D00203
DB00681
DivK1c_007045
EINECS 215-742-2
Fungilin
Fungisome
Fungisone
Fungizone
Fungizone (TN)
Halizon
HMS1569A22
HSDB 3008
HSDB 3008 IAB
I06-0257
KBio1_001989
KBio2_000551
KBio2_003119
KBio2_005687
KBioGR_002298
KBioSS_000551
Liposomal amphotericin b
Liposomal Amphotericin B
LMPK06000002
LNS-AmB
LS-187721
LS-93
MLS002702966
MolPort-006-392-260
Mysteclin-F
NCGC00014913
NCGC00090808-01
NCGC00098014-01
NCGC00179595-01
NCI527017
NCI60_004288
NCIStruc1_001042
NCIStruc2_000920
NKTR-024
NS 718
NSC 527017
NSC527017
NSC-527017
Prestwick_721
Prestwick0_000410
Prestwick1_000410
Prestwick2_000410
Prestwick3_000410
SinuNase
SMP1_000302
SMR001566780
SPBio_000715
SPBio_002279
SpecPlus_000949
Spectrum_000111
Spectrum2_000818
Spectrum4_001779
ST50999656
UNII-7XU7A7DROE
|
|
| 44 |
|
Guaifenesin |
Approved, Investigational, Vet_approved |
Phase 3,Phase 2,Not Applicable |
|
93-14-1 |
3516
|
|
Synonyms:
3-(2-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-1,2-propanediol
3-(O-Methoxyphenoxy)-propanediol-1,2
3-O-Methoxyphenoxypropane 1:2-diol
Actifed C
Aeronesin
a-Glyceryl guaiacol ether
a-Glyceryl guaiacolate ether
alpha-Glyceryl guaiacol ether
alpha-Glyceryl guaiacolate ether
Amonidren
Amonidrin
Aresol
Benylin-e
Breonesin
Bronchol
Ether, guaiacol glyceryl
Glycerin ether
Glycerin guaiacolate
glycero-Guaiacol ether
Glycerol a-(2-methoxyphenyl) ether
Glycerol a-(O-methoxyphenyl)ether
Glycerol a-guaiacyl ether
Glycerol a-guiacyl ether
Glycerol a-monoguaiacol ether
Glycerol guaiacolate
Glycerol mono(2-methoxyphenyl) ether
Glycerol-a-guajakolether
Glycerol-alpha-guajakolether
Glyceryl ether, guaiacol
Glyceryl guaiacol
Glyceryl guaiacol ether
Glyceryl guaiacolate
Glyceryl guaiacolate ether
Glyceryl guaiacyl ether
Glyceryl guaicolate
|
Glyceryl guiacolate
Glycerylguaiacol
Guaiacol glycerol ether
Guaiacol glyceryl ether
Guaiacolate, glycerol
Guaiacolglicerinetere
Guaiacuran
Guaiacurane
Guaiacyl glyceryl ether
Guaiamar
Guaianesin
Guaicol glycerine ether
Guaicol glyceryl ether
Guaifenesine
guaiphenesin
Guaiphenesin
Guaiphenesine
Guaiphenezine
Guaiphesin
Guiatuss
Humibid
Hustosil
Hytuss
Methoxypropanediol
Methphenoxydiol
Metossipropandiolo
O-Methoxyphenyl glyceryl ether
Organidin NR
P-Cresyl acetate
Pneumomist
Propanosedyl
Reduton
Robitussin
Scott tussin
Scott-tussin
ScottTussin
|
|
| 45 |
|
Dextromethorphan |
Approved |
Phase 3 |
|
125-71-3 |
5360696
5362449
|
|
Synonyms:
( )-3-Methoxy-N-methylmorphinon
( )-cis-1,3,4,9,10,10a-Hexahydro-6-methoxy-11-methyl-2H-10,4alpha-iminoethanophenanthren
(-)-3-Methoxy-N-methylmorphinan
(+)-3-Methoxy-17-methylmorphinan
(+)-dextromethorphan
(9alpha,13alpha,14alpha)-17-methyl-3-(methyloxy)morphinan
125-69-9 (hydrobromide)
125-70-2
125-71-3
18046-32-7
18609-21-7 (hydrochloride)
32062-10-5
3-Methoxy-17-methyl-9alpha,13alpha,14alpha-morphinan
3-Methoxy-17-methylmorphinan
4-21-00-01367 (Beilstein Handbook Reference)
6700-34-1 (hydrobromide, mono-hydrate)
9alpha,13alpha,14alpha-Morphinan, 3-methoxy-17-methyl- (8CI)
AC-13098
AC1L1EYT
Albutussin
Antussan
BA 2666
Balminil DM
Balminil DM Children
Bayer select flu relief
Bayer select head & chest cold
Bayer select night time cold
Benylin Adult Formula Cough Suppressant
Benylin DM
Benylin DM 12 Hour
Benylin DM for Children
Benylin DM for Children 12 Hour
Benylin Pediatric Cough Suppressant
BPBio1_000503
BRD-K33211335-337-03-7
BRN 0088549
BSPBio_000457
C06947
Calmylin #1
Canfodion
Cerose-DM
CHEBI:128891
CHEBI:4470
CHEBI:580686
CHEMBL22207
CHEMBL52440
Chloraseptic DM
CID3008
CID5360696
CID5362449
Contac day & night cold/flu day caplets
Contac jr. non-drowsy formula
Contac nighttime cold medicine
Contac severe cold formula maximum strength
Contac severe cold formula non-drowsy
Coricidin syrup
Cosylan
Cough-X
Creo-Terpin
D03742
DB00514
DEA No. 9210
Delsym
Delsym Cough Formula
delta-Methorphan
Delta-Methorphan
Demorphan
Demorphan hydrobromide
Demorphan Hydrobromide
Demorphine
Destrometerfano
Destrometerfano [Dcit]
Destrometerfano [DCIT]
Dex
Dextromethorfan
Dextromethorfan [Czech]
dextromethorphan
Dextromethorphan
Dextromethorphan (USP)
Dextromethorphan [USP:INN:BAN]
Dextromethorphan bromhydrate
Dextromethorphan Bromhydrate
Dextromethorphan bromide
Dextromethorphan Bromide
Dextromethorphan hydrobromide
Dextromethorphan hydrobromide monohydrate
Dextromethorphan hydrobromide oros tablets
Dextromethorphan hydrobromide, (+-)-isomer
Dextromethorphan hydrobromide, monohydrate
Dextromethorphan hydrochloride
Dextromethorphan, (+-)-isomer
Dextromethorphane
Dextrométhorphane
Dextromethorphane [INN-French]
Dextromethorphanum
Dextromethorphanum [INN-Latin]
Dextrometorfano
Dextrometorfano [INN-Spanish]
Dextrometorphan
Dextromorphan
Dexyromethorphan
Diabe-Tuss DM Syrup
Dimacol
Dimetapp DM
DM
d-Methorphan
|
D-methorphan
D-Methorphan
D-Methorphan hydrobromide
D-Methorphan Hydrobromide
Dormetan
Dormethan
Drixoral cough
Drixoral cough & congestion
Drixoral cough & sore throat
DXM
EINECS 204-751-7
EINECS 204-752-2
Endotussin-NN
Endotussin-NN pediatric
Hihustan M.
HMS2090C08
Hold
Hold DM
HSDB 3056
Hydrobromide, dextromethorphan
Hydrochloride, dextromethorphan
Koffex DM
Levomethorphan
Levomethorphan [Ban:Dcf:Inn]
Levomethorphan [BAN:DCF:INN]
Levomethorphan [INN:BAN:DCF]
Levomethorphane
Levomethorphane [INN-French]
Levomethorphanum
Levomethorphanum [INN-Latin]
Levometorfano
Levometorfano [INN-Spanish]
l-Methorphan
L-Methorphan
Lopac0_000337
Lopac-D-2531
LS-91837
LS-91838
Medicon
Methorate
Methorate Hydrobromide
Methorphan
Metrorat
MLS000758303
MolPort-003-940-943
MolPort-004-285-957
Morphinan, 3-methoxy-17-methyl-, (9-alpha,13-alpha,14-alpha)- (9CI)
Naldecon-DX
NCGC00015333-01
NCGC00015333-02
NCGC00015333-04
NCGC00162126-01
Novahistex DM
Novahistine DM
Ornex severe cold formula
Orthoxicol
PediaCare 1
PediaCare cough-cold formula
Pertussin CS Children's Strength
Pertussin DM Extra Strength
Prestwick_686
Prestwick0_000359
Prestwick1_000359
Prestwick2_000359
Prestwick3_000359
Racemethorphan
RACEMETHORPHAN
Robitussin CF
Robitussin cold & cough
Robitussin cough calmers
Robitussin DM
Robitussin maximum strength cough
Robitussin Maximum Strength Cough Suppressant
Robitussin Pediatric
Robitussin pediatric cough
Robitussin pediatric cough & cold
Robitussin Pediatric Cough Suppressant
Robitussin pediatric night relief
Romilar
Rondec DM
Ru-tuss expectorant
SPBio_002378
St. joseph cough syrup
Sucrets 4 Hour Cough Suppressant
Sudafed cough syrup
Triaminic
Triaminic DM Long Lasting for Children
Trind-DM
Trocal
Tusilan
Tussade
Tussar DM
Tussi-organidin
Tussi-organidin DM NR
Tussi-organidin DM-S NR
Tylenol cold and flu multi-symptom
Tylenol cold and flu no drowsiness
Tylenol cold no drowsiness
Tylenol cough + decongestant liquid
Tylenol cough liquid
Tylenol flu no drowsiness gelcaps
UNII-7355X3ROTS
Vicks 44 Cough Relief
viro-Med
δ-methorphan
|
|
| 46 |
|
Morphine |
Approved, Investigational |
Phase 3,Not Applicable |
|
57-27-2 |
5288826
|
|
Synonyms:
(-)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(-)-Heroin hydrochloride
(−)-morphine
(-)-Morphine
(-)Morphine sulfate
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-didehydro-4,5-Epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-epoxy-N-methyl-7-morphinen-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12bs)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
(7R,7AS,12BS)-3-METHYL-2,3,4,4A,7,7A-HEXAHYDRO-1H-4,12-METHANO[1]BENZOFURO[3,2-E]ISOQUINOLINE-7,9-DIOL
17-methyl-7,8-didehydro-4,5alpha-epoxymorphinan-3,6alpha-diol
4,5alpha-Epoxy-17-methyl-7-morphinen-3,6alpha-diol
47106-99-0
4-methyl-(13R,14S)-12-oxa-4-azapentacyclo[9.6.1.01,13.05,17.07,18]octadeca-7(18),8,10,15-tetraene-10,14-diol
57-27-2
6211-15-0 (sulfate (2:1) (salt) pentahydrate)
64-31-3
64-31-3 (sulfate (2:1) (salt) anhydrous)
7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
7,8-Didehydro-4,5-epoxy-17-methyl-morphinan-3,6-diol
8053-16-5
85201-37-2
Anhydrous morphine
Apokyn
Astramorph PF
Avinza
BIDD:GT0147
C01516
CCRIS 5762
CHEBI:17303
CHEMBL70
Chloride, morphine
CID5288826
Contin, MS
Cube juice
D-(-)-Morphine
DB00295
DEA No. 9300
Depodur
DepoDur
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dolcontin
Dreamer
Dulcontin
Duramorph
Duramorph PF
Duromorph
EINECS 200-320-2
Epimorph
Hard stuff
Heroin hydrochloride
Heroine hydrochloride
Hocus
|
HSDB 2134
Infumorph
Kadian
l-Morphine
LS-91748
M.O.S
Meconium
M-Eslon
MOI
MolPort-003-849-273
morfina
Morfina
Morfina [Italian]
Morphia
Morphin
Morphin [German]
Morphina
Morphina [Italian]
morphine
Morphine [BAN]
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine Sulfate
MORPHINE SULFATE
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
MORPHINE, (5A,6A)-7,8-DIDEHYDRO-4,5-EPOXY-17-METHYLMORPHINIAN-3,6-DIOL, MORPHIUM, MORPHIA, DOLCONTIN, DUROMORPH, MORPHINA, NEPENTHE
Morphinism
Morphinum
Morphitec
Morphium
Morpho
Moscontin
Ms Contin
MS Contin
Ms Emma
MS/L
MS/S
MSIR
nchembio.317-comp1
nchembio.64-comp1
Nepenthe
NSC11441
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
Oramorph SR
Ospalivina
Rescudose
RMS
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
SDZ 202-250
SDZ202-250
Statex
Statex Drops
Statex SR
Sulfate, morphine
UNII-76I7G6D29C
Unkie
|
|
| 47 |
|
Ondansetron |
Approved |
Phase 3,Phase 2,Not Applicable |
|
99614-02-5 |
4595
|
|
Synonyms:
(RS)-1,2,3,9-Tetrahydro-9-methyl-3-(2-methylimidazol-1-ylmethyl)carbazol-4-one
1,2,3,9-Tetrahydro-9-methyl-3-((2-methyl-1H-imidazol-1-yl)methyl)-4H-carbazol-4-one
103639-04-9 (mono-hydrochloride dihydrate)
108303-49-7
116002-70-1
99614-01-4 (mono-hydrochloride)
99614-02-5
9-Methyl-3-(2-methyl-imidazol-1-ylmethyl)-1,2,3,9-tetrahydro-carbazol-4-one
9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-1,2,3,9-tetrahydro-4H-carbazol-4-one
9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1H-carbazol-4-one
AB00373674
AC1L1IIM
AKOS000599484
Apo-ondansetron
BAS 00717177
BPBio1_001118
BRD-A19736161-001-01-8
BRD-A19736161-003-03-0
BRN 3622981
BSPBio_001016
C07325
C18H19N3O
CBDivE_008994
CHEMBL46
CID4595
CPD001307702
D00456
DB00904
DESMETHYLONDANSETRON
Dihydrate, ondansetron monohydrochloride
GR 38032
GR 38032X
GR38032F
GR-38032F
HMS2090H16
Hydrochloride, ondansetron
I06-0687
I06-1329
L000456
LS-172305
LS-51878
|
MolPort-001-944-253
Monohydrochloride dihydrate, ondansetron
Monohydrochloride, ondansetron
NCI60_022780
Novo-ondansetron
ondansetron
Ondansetron (JAN/USP/INN)
ondansetron (Zofran)
Ondansetron [USAN:INN:BAN]
Ondansetron hydrochloride
Ondansetron monohydrochloride
Ondansetron monohydrochloride dihydrate
Ondansetron, (+,-)-isomer
Ondansetron, (+,-)-Isomer
Ondansetron, (R)-isomer
Ondansetron, (S)-isomer
Oprea1_435466
Oprea1_852372
PHL-ondansetron
PMS-ondansetron
Prestwick0_001058
Prestwick1_001058
Prestwick2_001058
Prestwick3_001058
Ratio-ondansetron
SAM002589958
Sandoz ondansetron
SN-307
SPBio_002938
STK370548
STOCK4S-10990
TimTec1_001750
TL8006071
UNII-4AF302ESOS
Zofran
ZOFRAN IN PLASTIC CONTAINER
Zofran odt
Zofran ODT
Zofran ODT (TN)
Zophren
Zudan
|
|
| 48 |
|
Lenograstim |
Approved, Investigational |
Phase 3,Phase 2,Phase 1,Not Applicable |
|
135968-09-1 |
|
|
Synonyms:
G-CSF (CHO cell derived)
Glycosylated recombinant G-CSF
Glycosylated recombinant granulocyte colony stimulating factor
Granulocyte colony stimulating factor 3 (CHO cell derived)
|
Granulocyte colony-stimulating factor lenograstim
Lenograstim (genetical recombination)
Lenograstim rDNA
|
|
| 49 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable |
|
6055-19-2, 50-18-0 |
2907
|
|
Synonyms:
(-)-Cyclophosphamide
(+-)-Cyclophosphamide
(RS)-Cyclophosphamide
1-(bis(2-chloroethyl)amino)-1-oxo-2-aza-5-oxaphosphoridine
1-Bis(2-chloroethyl)amino-1-oxo-2-aza-5-oxaphosphoridin
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
4-Hydroxy-cyclophosphan-mamophosphatide
50-18-0
60007-95-6
6055-19-2 (monohydrate)
75526-90-8
AC1L1EQQ
AI3-26198
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
ASTA B518
B 518
B-518
bis(2-Chloroethyl)phosphami de cyclic propanolamide
bis(2-Chloroethyl)phosphamide cyclic propanolamide ester
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
BRN 0011744
BSPBio_002099
C 0768
C07888
C7H15Cl2N2O2P
CB 4564
CB-4564
CCRIS 188
CHEBI:4027
CHEMBL32520
CHEMBL88
Ciclofosfamida
Ciclofosfamida [INN-Spanish]
Ciclofosfamide
Ciclophosphamide
Ciclophosphamide [INN]
CID2907
Clafen
Claphene
CP
CPA
CTX
CY
Cycloblastin
Cyclophosphamid
cyclophosphamide
Cyclophosphamide
Cyclophosphamide (anhydrous form)
Cyclophosphamide (anhydrous)
Cyclophosphamide (INN)
Cyclophosphamide (TN)
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (+-)-Isomer
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamides
Cyclophosphamidum
Cyclophosphamidum [INN-Latin]
Cyclophosphan
Cyclophosphane
Cyclophosphanum
Cyclophosphoramide
Cyclostin
Cyklofosfamid
Cyklofosfamid [Czech]
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan (TN)
|
Cytoxan Lyoph
D,L-Cyclophosphamide
D07760
DB00531
DivK1c_000246
EINECS 200-015-4
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
EU-0100238
Genoxal
Hexadrin
HMS2090A12
HSDB 3047
IDI1_000246
KBio1_000246
KBio2_001338
KBio2_003906
KBio2_006474
KBio3_001319
KBioGR_000888
KBioSS_001338
Ledoxina
Lopac0_000238
Lopac-C-0768
LS-1302
LS-99787
Lyophilized Cytoxan
Mitoxan
MolPort-001-783-420
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
NCGC00015209-01
NCGC00015209-03
NCGC00015209-06
NCGC00091741-02
NCGC00091741-03
NCI60_002097
NCI-C04900
Neosar
NINDS_000246
NSC 26271
NSC26271
NSC-26271
NSC273033
NSC273034
Occupation, cyclophosphamide exposure
Procytox
RCRA waste no. U058
Rcra waste number U058
Rcra Waste Number U058
Revimmune
S1217_Selleck
Semdoxan
Sendoxan
Senduxan
SK 20501
SPBio_001071
Spectrum_000858
Spectrum2_001146
Spectrum3_000370
Spectrum4_000304
Spectrum5_000795
STK177249
STOCK2S-91217
UNII-6UXW23996M
WLN: T6MPOTJ BO BN2G2G
Zyklophosphamid
Zyklophosphamid [German]
|
|
| 50 |
|
Captopril |
Approved |
Phase 3 |
|
62571-86-2 |
44093
|
|
Synonyms:
(2S)-1-(3-Mercapto-2-methylpropionyl)-L-proline
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylate
(2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-Methyl-3-sulfanylpropanoyl]pyrrolidine-2-carboxylic acid
(2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl]pyrrolidine-2-carboxylate
(2S)-1-[(2S)-2-Methyl-3-sulphanylpropanoyl]pyrrolidine-2-carboxylic acid
(S)-1-(3-mercapto-2-Methyl-1-oxopropyl)-L-proline
(S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
(S)-1-(3-Mercapto-2-methyl-1-oxo-propyl)-L-proline
[2S]-1-[3-Mercapto-2-methylpropionyl]-L-proline
1-((2S)-3-Mercapto-2-methylpropionyl)-L-proline
1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline
1-(D-3-Mercapto-2-methyl-1-oxopropyl)-L-proline (S,S)
1-[(2S)-2-methyl-3-sulfanylpropanoyl]-L-proline
1j37
3-Mercapto-2-methylpropionyl-proline
62571-86-2
AC-12047
AC1L2B4L
AC1Q29GZ
AC1Q5R48
Acediur
Aceplus
Acepress
Acepril
Alopresin
Apopril
Apopril (TN)
Asisten
BB_NC-2104
BIM-0050290.0001
BPBio1_000063
BRD-K54529596-001-04-0
BSPBio_000057
BSPBio_002976
C 4042
C4042_SIAL
C4042_SIGMA
C8856_SIAL
C9H15NO3S
Capoten
Capoten (TN)
Captolane
captopril
Captopril (JP15/USP/INN)
Captopril [USAN:INN:BAN:JAN]
Captoprilum
Captoprilum [INN-Latin]
Captopryl
Captoril
Captril
Cesplon
CHEBI:3380
CHEMBL1560
CHEMBL82
CID44093
CP
CPD000059061
CPD0-2067
D00251
D-2-Methyl-3-mercaptopropanoyl-L-proline
D-3-mercapto-2-Methylpropanoyl-L-proline
D-3-Mercapto-2-methylpropanoyl-L-proline
D-3-Mercapto-2-methylpropionylproline
DB01197
Dilabar
DivK1c_000208
EINECS 263-607-1
EU-0100302
FT-0082749
|
Garranil
Garranil (discontinued)
Hipertil
HMS1921C12
HMS2089P19
HMS2092I12
HMS500K10
HSDB 6527
Hypertil
IDI1_000208
Isopresol
KBio1_000208
KBio2_001168
KBio2_003736
KBio2_006304
KBio3_002196
KBioGR_001321
KBioSS_001168
L-Captopril
Lopac0_000302
Lopac-C-4042
Lopirin
Lopirin [Switzerland]
Lopril
LS-137465
MCO
MLS000069484
MLS001076488
MolPort-001-794-639
N-[(S)-3-Mercapto-2-methylpropionyl]-L-proline
NCGC00015235-01
NCGC00015235-02
NCGC00023654-03
NCGC00023654-04
NCGC00023654-05
NCGC00023654-06
NCGC00023654-07
NCGC00023654-08
NCGC00023654-09
NCGC00023654-10
NINDS_000208
Prestwick_103
Prestwick3_000019
SA 333
SAM002564201
SMP1_000056
SMR000059061
SPBio_001022
Spectrum_000688
SPECTRUM1500682
Spectrum2_001211
Spectrum3_001388
Spectrum4_000811
Spectrum5_001587
SQ 14,225
SQ 14225
SQ-14,225
SQ-14,534
SQ-14225
SQ-14534
ST079562
STK802012
Tenosbon
Tensiomin
Tensobon
Tensoprel
UNII-9G64RSX1XD
UPCMLD-DP003
UPCMLD-DP003:001
X8Z
|
|
Interventional clinical trials:
(show top 50)
(show all 393)
| # |
Name |
Status |
NCT ID |
Phase |
Drugs |
| 1 |
Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A |
Completed |
NCT00221039
|
Phase 4 |
Methoxsalen+ECP |
| 2 |
Study of ONTAK (Denileukin Diftitox) in Previously Treated Cutaneous T-Cell Lymphoma Patients |
Completed |
NCT00051012
|
Phase 4 |
ONTAK |
| 3 |
Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients |
Completed |
NCT00050999
|
Phase 4 |
ONTAK |
| 4 |
Study Evaluating Two Dose Levels of Targretin Capsules in Patients With Refractory Cutaneous T-cell Lymphoma (CTCL) |
Completed |
NCT01007448
|
Phase 4 |
bexarotene;bexarotene |
| 5 |
Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas |
Recruiting |
NCT02323659
|
Phase 4 |
Methotrexate;Interferon Alfa-2b |
| 6 |
PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides |
Terminated |
NCT00630903
|
Phase 4 |
PUVA (8MOP + UVA) + IFN;PUVA (8-MOP + UVA) |
| 7 |
Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain |
Unknown status |
NCT01316744
|
Phase 3 |
ketamine hydrochloride |
| 8 |
Early Hospital Discharge or Standard Inpatient Care in Cancer Patients Receiving Antibiotics for Febrile Neutropenia |
Unknown status |
NCT00445497
|
Phase 3 |
amoxicillin-clavulanate potassium;ciprofloxacin |
| 9 |
Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia |
Unknown status |
NCT00020865
|
Phase 3 |
cefepime hydrochloride;levofloxacin |
| 10 |
PUVA Maintenance Therapy in Mycosis Fungoides |
Completed |
NCT01686594
|
Phase 3 |
8-methoxypsoralen |
| 11 |
A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) |
Completed |
NCT01578499
|
Phase 3 |
Brentuximab Vedotin;Methotrexate;Bexarotene |
| 12 |
Study of Oral LBH589 in Adult Patients With Refractory Cutaneous T-Cell Lymphoma |
Completed |
NCT00425555
|
Phase 2, Phase 3 |
Panobinostat |
| 13 |
Study of Oral LBH589 in Adult Patients With Refractory/Resistant Cutaneous T-Cell Lymphoma |
Completed |
NCT00490776
|
Phase 2, Phase 3 |
LBH589 |
| 14 |
Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial |
Completed |
NCT00750009
|
Phase 3 |
|
| 15 |
American Ginseng in Treating Patients With Fatigue Caused by Cancer |
Completed |
NCT00719563
|
Phase 3 |
American ginseng |
| 16 |
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain |
Completed |
NCT00666211
|
Phase 3 |
|
| 17 |
Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer |
Completed |
NCT00661999
|
Phase 3 |
sodium ferric gluconate complex in sucrose |
| 18 |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
Completed |
NCT00538850
|
Phase 3 |
Fentanyl sublingual spray;Placebo |
| 19 |
Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer |
Completed |
NCT00070382
|
Phase 3 |
darbepoetin alfa;epoetin alfa |
| 20 |
Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment |
Completed |
NCT00008359
|
Phase 3 |
caspofungin acetate;liposomal amphotericin B |
| 21 |
Levofloxacin to Prevent Infection Following Chemotherapy in Treating Patients With Solid Tumors or Lymphoma |
Completed |
NCT00005590
|
Phase 3 |
levofloxacin |
| 22 |
Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients |
Completed |
NCT00003938
|
Phase 3 |
liposomal amphotericin B |
| 23 |
Treatment for Chronic Pain in Patients With Advanced Cancer |
Completed |
NCT00003687
|
Phase 3 |
dextromethorphan hydrobromide;morphine sulfate |
| 24 |
Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment |
Completed |
NCT00006348
|
Phase 3 |
ondansetron |
| 25 |
Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases |
Completed |
NCT00438958
|
Phase 3 |
|
| 26 |
Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant |
Completed |
NCT00305851
|
Phase 3 |
|
| 27 |
Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation |
Completed |
NCT00004230
|
Phase 3 |
captopril;cyclophosphamide |
| 28 |
Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation |
Completed |
NCT00003883
|
Phase 3 |
fluconazole;itraconazole |
| 29 |
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation |
Completed |
NCT00045292
|
Phase 3 |
acyclovir;acyclovir sodium;valacyclovir |
| 30 |
Efficacy of Doxycycline in the Treatment of Early Stages of Mycosis Fungoides |
Recruiting |
NCT03454945
|
Phase 3 |
Vibramycin |
| 31 |
FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) |
Recruiting |
NCT02448381
|
Phase 3 |
SGX301 (synthetic hypericin);Placebo |
| 32 |
Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL |
Recruiting |
NCT02811783
|
Phase 3 |
Naloxone Hydrochloride Lotion, 0.5%;Placebo Lotion |
| 33 |
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer |
Active, not recruiting |
NCT00003816
|
Phase 2, Phase 3 |
busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa |
| 34 |
Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome |
Terminated |
NCT00127881
|
Phase 3 |
HuMax-CD4 (zanolimumab) |
| 35 |
Ultraviolet Light Therapy Using Methoxsalen With or Without Bexarotene in Treating Patients With Mycosis Fungoides |
Terminated |
NCT00056056
|
Phase 3 |
bexarotene;methoxypsoralen |
| 36 |
Lenalidomide Maintenance Post-debulking in Advanced CTCL |
Terminated |
NCT01098656
|
Phase 3 |
lenalidomide |
| 37 |
Combination Chemotherapy With or Without Etoposide in Treating Older Patients With Non-Hodgkin's Lymphoma |
Terminated |
NCT00060385
|
Phase 2, Phase 3 |
CHOP regimen;EPOCH regimen;cyclophosphamide;doxorubicin hydrochloride;etoposide;prednisone;vincristine sulfate |
| 38 |
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant |
Terminated |
NCT00324324
|
Phase 3 |
moxifloxacin hydrochloride;Placebo |
| 39 |
Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma |
Withdrawn |
NCT01386398
|
Phase 3 |
bortezomib;vorinostat |
| 40 |
Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome |
Unknown status |
NCT00157274
|
Phase 2 |
alemtuzumab |
| 41 |
Combination Chemotherapy in Patients With Advanced or Recurrent Mycosis Fungoides |
Unknown status |
NCT00002557
|
Phase 2 |
CHOP regimen;doxorubicin hydrochloride;etoposide;leucovorin calcium;methotrexate |
| 42 |
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas |
Unknown status |
NCT01805037
|
Phase 1, Phase 2 |
brentuximab vedotin |
| 43 |
Chemotherapy and Photodynamic Therapy in Treating Patients With Cutaneous T-Cell Lymphoma |
Unknown status |
NCT00030589
|
Phase 2 |
bexarotene;methoxsalen |
| 44 |
Combination Chemotherapy Followed by Donor Bone Marrow Transplant or Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer or Genetic Disorders |
Unknown status |
NCT00008307
|
Phase 2 |
cyclosporine;fludarabine phosphate;melphalan;methylprednisolone;mycophenolate mofetil |
| 45 |
Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma |
Unknown status |
NCT02213861
|
Phase 2 |
SHAPE |
| 46 |
Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia |
Unknown status |
NCT00008164
|
Phase 2 |
|
| 47 |
External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases |
Unknown status |
NCT00637637
|
Phase 2 |
indinavir sulfate;ritonavir |
| 48 |
Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides |
Completed |
NCT00168064
|
Phase 2 |
mechlorethamine-MCH (nitrogen mustard) |
| 49 |
Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome |
Completed |
NCT02243579
|
Phase 2 |
|
| 50 |
An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides |
Completed |
NCT00535470
|
Phase 2 |
0.04% Mechlorethamine gel |
Inferred drug relations via
UMLS
73
/
NDF-RT
51
:
Cell-based therapeutics:
Data from LifeMap, the Embryonic Development and Stem Cells Database
Stem-cell-based therapeutic approaches for Mycosis Fungoides:
Embryonic/Adult Cultured Cells Related to Mycosis Fungoides:
|
